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 ABSTRACT 
Mary Elizabeth Ritchey 
Central line-associated blood-stream infections and ventilator-associated 
pneumonias:  changing infection rate across duration of hospitalization and with 
different definitions of time at risk 
(Under the direction of Michele L. Jonsson Funk) 
 
Background: Patients with mechanical ventilators (MV) and central lines (CL) have 
increased rates of infection during hospitalization compared with other patients.  Our 
objectives were to 1) model changing infection rates varied over device duration 
adjusting for changes in risk factor distribution throughout that time and 2) to 
determine whether changing rate models were a more appropriate analysis than 
constant rate models. 
Methods: Electronic healthcare records of inpatients at UNC Hospitals between 
January 1, 2002 and December 31, 2007 who used central line(s) or mechanical 
ventilator were collected.  We modeled changing rates across duration of device 
placement via discrete-time hazards regression, adjusting for age, gender, 
race/ethnicity, comorbidities, patient location, and hospital service. We compared 
changing rate to constant rate models via differences in error and F-tests. 
Results:  MV-associated infection peaked around 7 days; CL-associated infection 
peaked around 14 days.  Rates varied between 2 and 10 infections per 1000 device-
days.  MV infection rates were higher among patients with trauma, central venous 
catheters, or blood-stream infection.  Infection rates were lower on the floor 
compared to ICU.  After 11 days, medical and pediatric patients had decreased MV 
 infection rates compared with surgical patients.  With CL, rate of infection was higher 
in Black individuals, and patients in intensive care units (ICUs) or on a surgical 
service.  In the first week, males had increased infection risk compared to females. 
Changing rate models fit the observed rates better than constant rate models for 
surgical and ICU patients, and the UNC Hospitals overall population.  Various 
definitions of device exposure indicated that changing rate models were better for at 
least some patient groups.  
Conclusion: Variation in rates across duration of time at risk remained after 
adjusting for the changing population at risk. Awareness of patients at increased 
risk, monitoring throughout hospitalization and timing interventions and surveillance 
appropriately could reduce the incidence of MV and CL associated infections. 
Investigators should be aware that when comparing patient groups or different 
hospitals without accounting for the changing rate of infection across device duration 
estimates may not be meaningful. 
 To my sister, Amanda Jo Lerand, for always encouraging me on my path, 
consistently reminding me that it is the right one, and for choosing her own road with 
the same boldness and determination - for believing that even though there is light 
on this path of life, it doesn’t mean that the road will look the same for each of us.
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I. INTRODUCTION
A. Device-associated nosocomial infections 
 In 2002, there were 1.7 million infections in hospitalized patients [1].  
Nosocomial infections (NI) occur in up to 10% of all patients in the hospital [2]. 
Approximately 15% of all NI are pneumonia and another 14% are blood-stream 
infections (BSI) [1]. Thus, pneumonia and BSI represent a significant portion of the 
problem of NI and a large proportion of both are linked with specific medical devices 
[3]. Mechanical ventilation accounts for 83% of cases of nosocomial pneumonia. 
And, 87% of primary BSI are found in patients with central venous access or “central 
lines.” [3] 
 Patients with device-associated pneumonia or BSI are at increased risk of 
death in the hospital [4-9]. In 2002, of the estimated 99,000 deaths associated with 
NI, 36,000 were from pneumonia and 31,000 from BSI [1]. These two medical 
devices are thus associated with two-thirds of NI-related mortality. 
 To provide perspective for these numbers, we examine the national mortality 
statistics.  There were an estimated 2 million deaths in the United States in 2006.  
The top 10 causes of death are listed in Table 1, below [10].  While NI is not counted 
as a cause of death for national statistics and it would change the numbers in the 
table if it were included, we can see that 99,000 associated deaths could rank NI 
above diabetes as the sixth leading cause of death in the country.  The 67,000 
deaths from nosocomial pneumonia and BSI alone could rank as the eighth leading 
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cause of death.  The 57,000 device-associated pneumonias BSIs could continue to 
rank eighth.  Thus, the morbidity and mortality from these device-associated NI is 
substantial.  With greater study and application in this field, there is the possibility of 
decreasing incidence and mortality, saving thousands of lives annually.  
Table 1.  Top 10 Causes of Death in the United States in 2006. 
Rank Cause of Death 
Number of 
people 
Percent of 
all deaths 
1 Diseases of heart  631,636 26.0 
2 Malignant neoplasms  559,888 23.1 
3 Cerebrovascular diseases  137,119 5.7 
4 Chronic lower respiratory diseases  124,583 5.1 
5 Accidents (unintentional injuries)  121,599 5.0 
6 Diabetes mellitus  72,449 3.0 
7 Alzheimer's disease  72,432 3.0 
8 Influenza and pneumonia  56,326 2.3 
9 Nephritis, nephrotic syndrome and nephrosis  45,344 1.9 
10 Septicemia  34,234 1.4 
*Table from National Vital Statistics Report, 57(14), 2009. 
 The purpose of this study is to the elucidate timing of the rates device-
associated infections during hospitalization.  The goal is to model changing rates of 
mechanical ventilator and central line infections and to determine whether changing 
rate models provide a more accurate portrayal of the incidence of infections over 
time than constant rate models.  We assess time-only models as well as models 
adjusting for patient characteristics, to determine whether variation in the rate of 
infection could be explained by changes in the patient population at risk across 
device duration.  We also assess models with different measures of device exposure 
time, to determine whether changing rates are affected by method of exposure 
assessment. 
B. Dissertation layout 
 In addition to this chapter, there are five primary sections in this dissertation.  
The next section contains Chapter II: a review of the literature.  This section reviews 
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the current knowledge about risk factors for ventilator-associated pneumonia and 
central line-associated blood stream infection, the potential for measuring changing 
rates of nosocomial infection, and the measures of device exposure in nosocomial 
infection literature.  Previous studies of nosocomial infection at UNC Hospitals are 
also included in this section. 
 The statement of aims is in Chapter III.  It provides the scope of work along 
with specific aims and hypotheses to address the purpose of the research.  Chapter 
IV provides the details of the methods used for this dissertation.  An overview and 
description of the study population from UNC Hospitals begins the section.  Analysis 
methods for each specific aim follow the overview. 
 The Results section consists of Chapters V-VIII.  Chapter IX is the last 
substantive section of the dissertation.  It provides the conclusions drawn based on 
this project and indicates future directions for continuation of the work. 
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II. REVIEW OF THE LITERATURE 
A. Background 
Device specific healthcare-associated infection surveillance 
 National healthcare-associated infection (HAI) surveillance began in the 
1970’s and an annual report was generated using accumulated data from 
contributing hospitals [1-4]. The annual report included central line-associated 
bloodstream infection (CLABSI) and ventilator-associated pneumonia (VAP), as well 
as other intensive care unit (ICU) infection rates. 
 Beginning in 1991, each facility reported rates as the total number of 
infections divided by the total number of days patients had the device placed 
(device-days) for each type of ICU, and the national surveillance report then 
provided the 10th, 25th, 50th, 75th, and 90th percentile rates for each type of ICU 
across all reporting facilities. Prior to that time, the rate denominator was the total 
number of days patients were in the ICU (patient-days). 
 While stratifying by type of ICU (and teaching hospitals versus not for 
medical-surgical ICUs), no delineation was made for patient case-mix between the 
hospitals. This means that small, rural hospitals with less severe patients were 
compared to larger, tertiary care centers without adjustment. Also, only one rate was 
reported per unit, assuming that the rate of device-associated infection was constant 
throughout the patients’ time in that ICU [2-4].
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 Beginning in 2005, the annual report also included rates for monitored 
devices on inpatient medical and medical/surgical wards and the percent of 
infections associated with specific categories of infection criteria [3,4]. Percentiles of 
utilization ratios, comparing days patients use devices to days patients are 
hospitalized were also included [4]. 
 The information presented in these annual reports is appropriate for 
surveillance, but does not provide a full adjustment for patient case-mix. We do not 
know whether adjusting for risk factors for VAP or CLABSI would significantly 
change which hospitals fall into higher (or lower) infection rate percentiles. We also 
do not know the effect of adjusting for a changing rate of infection across the 
duration of device placement. 
Other published literature compared with national surveillance 
 VAP and CLABSI rates presented in the published literature may use the 
device-days denominator required in national surveillance reports, or may use the 
patient-days denominator [1,5,6]. As neither device is removed when infection 
occurs, neither device-days nor patient-days specifically implies removal of the 
patient from the denominator for calculating rates. Authors may not adjust 
denominators for reported rates to reflect time when a patient already has an 
infection, and is thus unable to acquire an incident infection. Denominators not 
accounting for time with infection may be inflated, thus rates of device-associated 
infection may appear lower than actually occurring rates.  
 Published literature is also unclear in regards to whether multiple infections 
are captured per person.  Without specification, hospitals reporting multiple 
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infections may appear to have higher device-associated infection rates than 
compared to those reporting only the first infection for patients. 
B. Critical review of literature 
Ventilator-associated pneumonia (VAP) 
 Patients with mechanical ventilators (MV) are typically found in ICUs. 
Between 2006 and 2007 [4], national surveillance indicated MV were used most 
frequently in trauma ICUs (pooled mean of 0.58 ventilator-days per patient-day) and 
least often in coronary ICUs (0.27 ventilator days per patient-day). The pooled mean 
of VAP across all hospitals included in the national surveillance ranged from 2.1 
cases per 1000 vent-days in Pediatric Medical/Surgical ICUs to 10.7 per 1000 vent-
days in Burn ICUs [4]. Reported VAP across all ICUs ranged from 0.0 to 16.7 per 
1000 vent-days [4]. 
 Other studies reported a 5-28% risk of VAP during hospitalization [7-26]. 
These studies found rates as low as 2.5 per 1000 vent-days and as high as 57.6 per 
1000 vent-days. 
 Despite rates of pneumonia presented in these studies, there is some 
evidence that VAP does not occur at a constant rate across duration of MV. In one 
study, 3% of patients contracted VAP each day in the first week, 2% per day in the 
second week and 1% per day in subsequent weeks [27,28]. 
 Time to onset of infection ranged from a mean of 3.3 days to 32.7 days post-
MV insertion in adult ICUs [7-10,14,18,23,26]. Only two studies have reported time 
to onset of pneumonia in children: one with a mean of 8.9 days in the pediatric ICU 
and the other with a median of 37 days for preterm neonates in the neonatal ICU 
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[11,29]. 
 Some risk factors have consistently been associated with increased VAP 
rate, including presence of a central venous catheter or primary blood-stream 
infection, reintubation, aspiration, location and change of location within the 
hospital, tracheostomy, and patient positioning [8,9,11,13,21,27,30-33].  Others, 
such as age, gender, race/ethnicity, hospital service, and comorbidities have been 
identified as risk factors in some, but not all studies [9,13,14,21,31,32]. 
Central line-associated blood stream infections (CLABSI) 
 Approximately 5 million central lines (CL) are inserted in the United States 
each year, with infections occurring in 3-8% of patients [34].  Between 2006-2007 
[4], hospitals in the national surveillance reported that CL were used most often in 
surgical cardiothoracic ICUs (pooled mean 0.72 CL-days per patient-day) and least 
often in inpatient wards (range 0.09 CL-days per patient-day in rehabilitation ward to 
0.26 CL-days per patient-day in adult step-down units). The mean of CLABSI in 
these hospitals ranged from 0.5 per 1000 CL-days in rehabilitation wards to 5.6 per 
1000 CL-days in burn ICUs. Reported CLABSI ranged from 0.0 to 13.5 per 1000 CL-
days in all ICUs [4]. 
 Other studies reported rates of CLABSI ranging 0.7 to 18.5 per 1000 CL-days 
[15,23,25,35-38]. Four to 28% of all patients with CL developed BSI [22,36]. The 
average time to onset of infection was 20.4 days [39].  CLABSI was associated with 
a longer length of stay in the hospital, and, in some cases, increased mortality 
[22,23]. Studies to date did not look for or identify other risk factors. 
 No studies have been done looking at changes in the rate of CLABSI across 
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duration of CL placement. But, the longer mean time to infection implies that if a 
change in rate for CLABSI exists, it would occur over a longer duration of time 
compared with VAP. 
Device-days versus Patient-days 
 In September 2007, the Division of Healthcare Quality Promotion at the CDC 
published a paper in Infection Control and Hospital Epidemiology [5]. The article 
discussed differences in CLABSI rate estimates using patient-days compared with 
CL-days). In the NNIS sample of ICUs, using patient-days rather than CL-days led to 
an average 7% change in the rank of rate estimates among the reporting hospitals. 
On average for all hospitals, patient-days accurately represented 76% of “high” 
infection rate hospitals as having high CLABSI rates when compared with the CL-
days denominator.  The authors noted that as the device use ratio (percent of 
patients in the ICU who had CL) increased, the percentile error when using patient-
days as the denominator decreased. 
 In April 2006, the German equivalent to the Division of Healthcare Quality 
Promotion at the CDC found that rates of HAI were higher on the floors than in ICUs 
using device-days as denominators, but infection rates were much lower on floors 
when patient-days were the denominators [6]. The device use ratio is lower on the 
floors than in the ICUs; thus, the percentile error when using patient-days on the 
floors was expected to be large if device-days was considered the optimal measure. 
 Learning more about when device-associated HAI occur will enable us to 
tailor interventions to curtail these infections. By determining the changes in VAP 
and CLABSI rate across duration of device exposure, adjusted for known covariates 
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such as gender, age, patient location, and hospital service, infection control 
practitioners will be able to better utilize time and money in prevention and treatment 
of device-associated HAI. They will be able to determine how patient case-mix and 
severity contribute to their hospitals’ rates of infections, thus making their own 
surveillance rates more applicable to improving patient care. 
Changing rate across duration of exposure 
 Although most studies and the annual surveillance reports present constant 
rates of device-associated infections over time, there are a few small studies that 
indicate that the rate of device-associated infections may be changing throughout 
the duration of exposure [40,41].  
 Changing underlying hazard rates of VAP were reported in one study.  
Jaimes reported an increase over the first 10 days in an ICU and then a decrease 
and leveling-off for hazard rates at 20 days in the ICU [14].  These hazard rates 
were not adjusted for any potential confounders, and the rates of infection among 
different groups of patients at risk may vary across duration of MV. 
 Unfortunately, surveillance reports have been used to say that one hospital is 
‘better’ than another hospital because it has fewer infections [41]. Since surveillance 
reports and much of the published literature do not adjust for age, gender, patient 
severity, case mix, or changing rate of infection across duration of exposure, it is 
difficult to determine whether the rates presented are appropriate for comparison of 
facilities.  Analyzing the effect of changing rate across duration of device-exposure, 
and whether patient-days and device-days exhibit similar trends with changing rate 
and patient characteristics will help us to better understand the intricacies in 
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comparing device-associated HAI rates. 
Device-associated Infection Rates at UNC Hospitals 
 In 2006, there were 164,728 device-days logged for patients at UNC 
Hospitals.  The rate of VAP was 4.76 per 1000 ventilator-days (range: 0.91/1000 
days in the pediatric ICU to 11.67/1000 days in the surgical ICU). The rate of 
CLABSI was 3.89 per 1000 CL-days (range: 0.27/1000 days in burn unit to 
9.35/1000 days in the medical primary care unit) [unpublished data]. These rates are 
constant, calculated from the total number of days that all patients with a device had 
that device in place (including days after infection occurred and multiple infections in 
one person counting as multiple infections in the overall number) and fall below the 
10th percentile in the latest national surveillance report [4]. 
 In addition to the ICU infection rates, which could be compared with national 
surveillance reporting, the rates on the floors for CLABSI ranged from 1.11/1000 
days to 7.52/1000 days.  So, the low ICU infection rates at UNC Hospitals do not 
provide all of the information about infections associated with these devices.  
Previous studies of infection at UNC Hospitals 
 A few studies of HAI have been conducted previously using UNC Hospitals 
data.  Saviteer [42] discussed increased risk of HAI in elderly patients.  The authors 
found that patients over age 60 had HAI rates 49% higher than patients under age 
60.  A total of 4,031 infections occurred in 2,662 admissions over four years (1980-
84).  All HAI were included in the study. Respiratory infection rates and bloodstream 
infection rates as well as overall HAI rates increased with increasing age (by 
decade).  Duration of hospitalization (in three-day increments) was also assessed as 
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a risk factor for HAI.  HAI rates increased from days 2-4 to days 14-16, then 
decreased to days 23+.  No patient risk factors other than age were assessed in the 
study.  No specific information was provided for device-associated infections. 
 In 1989, Brawley [40], reported findings from an analysis of multiple HAI also 
using UNC Hospitals data from 1980 to 1984. They found that HAI occurred in 2.6% 
of patients at a rate of 4.5 infections per 1000 patient-days. There was an average of 
1.5 HAIs among those patients who had any infection. Twenty-nine percent of 
patients who developed HAI spent time in the ICU. Fifty-five percent of respiratory 
infections and 64% of BSI occurred in patients with more than one infection. Whites 
and females were more likely to have any HAI. Whites and males were more likely to 
have multiple HAI.  Age and duration of hospitalization were not associated with 
infection rate.  But, patients with more infections did have longer average hospital 
stays. 
 Weber [43] compared HAI found during surveillance in 1985-89 with HAI 
during 1980-84. Fewer HAI occurred in 1985-89 than in 1980-94.  Aside from 
pathogen analysis, other risk factors were not assessed as part of this study.  Again, 
no specific information was provided regarding device-associated infections. 
 In July 2007, Weber [44] compared VAP and other hospital acquired 
pneumonias at UNC Hospitals between 2000 and 2003.  Over 90% of VAP occurred 
in ICU patients while 67% of other pneumonias were in ICU patients. Less than 15% 
of VAP occurred in the first four days of hospitalization compared with 21% of other 
hospital-acquired pneumonias. Increasing rates of VAP were noticed with increasing 
time since hospital admission. 
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 Weber [45] also produced a study comparing the number of HAI using CDC-
recommended ICU surveillance compared with comprehensive hospital-wide 
surveillance. Using the CDC targeted surveillance, only 21.4% of CLABSI and 
37.9% of respiratory tract infections would have been found at UNC Hospitals during 
2004-2005. The overall number of infections at UNC Hospitals was much larger than 
what would have been reported to the CDC for inclusion in the national surveillance 
report. Twenty-one percent of respiratory tract infections and 37% of BSI were 
associated with medical devices. Most of the ICU infections were associated with 
devices. Device-associated infection rates were higher in ICUs than on floors. 
Infection rates in step-down units were more similar to floors than ICUs. Patient risk 
factors were not assessed as part of this study. 
C. Summary 
 Risk factors for VAP have been reported widely, but risk factors for CLABSI 
are less well known.  Changing risks throughout patient hospitalizations have not 
been widely investigated, as much of the literature revolves around small outbreaks 
and the national surveillance reporting. 
 UNC Hospitals have low rates of VAP and CLABSI, compared to the hospitals 
providing information for national surveillance.  UNC Hospitals are also monitoring 
infections throughout the entire facility, not just in ICUs.  To decrease rates of 
infection, targeted interventions may be necessary. 
 Device-associated HAI risk may fluctuate throughout a patient’s 
hospitalization.  If this is the case, then targeting interventions to times of increased 
HAI risk would be an efficient way to decrease infections. 
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 III. STATEMENT OF SPECIFIC AIMS 
 We modeled infection rates while accounting for fluctuations in the rate of 
device-associated hospital infections across the duration of device exposure.  We 
were interested in the rate of VAP and CLABSI over the time that patients were 
hospitalized.  We accounted for the variation in these device-associated rates by 
describing the rate of infection in short time periods (1-7 days) from device-
placement (or admission) to removal (or discharge) while accounting for age, 
gender, patient location, comorbidities (via ICD-9 codes) and hospital service (e.g. 
adult medical, adult surgical, pediatric).  We also accounted for these variations 
using four measures of device exposure duration to determine whether there were 
differences in infection rates by type of denominator. 
A. Specific aim 1 
 Aim: To clarify whether and how the rate of device-associated infections 
varies over duration of device exposure for patients who utilize MV or CL.  Data for 
this analysis came from a cohort of patients at UNC Hospitals with MV or CL 
between 1 January, 2002 and 31 December, 2007.  The denominator for this 
analysis was the number of days that the patient had the device without getting an 
infection. 
 Rationale: Mechanical ventilators and central venous catheters (central lines) 
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are among the top three devices associated with nosocomial infection. Many studies 
of HAI in the United States report a single, constant rate at each facility for each of 
these device-associated infection in each type intensive care unit.  But, device-
associated HAI rates are likely not constant throughout device exposure.  
Accounting for this changing of infection rate across duration of device exposure 
would allow us to more accurately determine when patients are at greatest risk for 
infection throughout hospitalization and to target interventions during that time. 
 Hypothesis: Our hypothesis was that the rate of VAP and CLABSI infections 
would fluctuate over the duration of utilization for MV and CL, respectively. We 
expected VAP and CLABSI to have different trajectories, but that the rates 
associated with each would increase over the first days of exposure then decrease 
to low, but constant rates of infection with subsequent use.  We also expected the 
infection rates to differ based on patients' age, gender, comorbidities, hospital 
service (e.g. adult medical, adult surgical, pediatric), and patient location (ICU or 
floor/step-down unit).  
B. Specific aim 2 
 Aim:  To determine the impact of modeling the changing rate of VAP and 
CLABSI across duration of device exposure compared to constant infection rates 
and whether the variation remained with different denominator choices. Data for this 
analysis was from the same cohort of patients at UNC Hospitals who had MV or CL 
between 2002 and 2007. 
 Rationale: If the rate of device-associated hospital acquired infection varies 
across the duration of exposure, then changing rate models would provide a better 
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fit to the observed incidence and bias could be introduced when comparing groups 
of patients without accounting for the variation in rates over time.  Because some 
hospitals use alternative measures of the duration of exposure, we also assessed 
these denominator choices to see if the potential for bias was indicated in all 
measures of device exposure.  
 Hypothesis:  Our hypothesis was that the changing rate of VAP or CLABSI 
would provide more meaningful estimates of the observed incidence than a constant 
rate of infection throughout device exposure.  A secondary, confirmatory hypothesis 
was that both constant and changing rates of infection would be higher when using 
device-days as a denominator compared with the patient-day denominator and that 
removing patients with infection from the population at risk would increase the 
estimated rates for both patient-days and device-days for all rate measures. 
 Because VAP and CLABSI were expected to differ based on patient 
characteristics and risk factors, we assessed various subpopulations of interest to 
determine whether the changing or constant rates provided meaningful estimates of 
the observed incidence in various target groups.  Our hypothesis was that the 
changing rate models would provide more meaningful estimates when there was 
greater variation in a target group across the duration of device exposure. 
Results layout 
 Chapters V and VI present the results from specific aim 1.  Chapter V is the 
manuscript for central line-associated bloodstream infection results; Chapter VI is 
the manuscript for ventilator-associated pneumonia results.  Chapters VII and VIII 
present the results from specific aim 2.  The ventilator-associated pneumonia results 
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are in manuscript form in Chapter VII.  And, Chapter VIII includes supplemental 
results for aim 2.  The information covered in Chapter VIII is presented in tabular and 
graphical form with short descriptions and covers VAP results not included in the 
Chapter VII manuscript as well as all CLABSI results from aim 2. 
 IV. METHODS 
A. Subject identification/sampling 
Source population: University of North Carolina (UNC) Hospitals data 
 UNC Hospitals has been collecting aggregate level data on device-associated 
HAI since 2002.  They have also been using an electronic medical record since the 
late 1970’s.  Since the electronic version is the medical record at UNC Hospitals, 
missing data is minimal.  Individual data is available to assess patient factors that 
influence HAI rates such as gender, age, race/ethnicity, comorbidities, patient 
location and hospital service (e.g. surgical or medical). 
Study setting and design 
 The source population for this study was all patients hospitalized at UNC 
Hospitals between 1 January, 2002 and 31 December, 2007 for at least 24 hours. 
The study population consisted of a retrospective cohort of all patients in the source 
population who utilized a CL or MV during their hospital stay.  There was no 
interaction between investigators and subjects and no new information was collected 
as part of the study.   
 Data from the source population was collected as part of usual care at UNC 
Hospitals (see Table 2). Device utilization was collected by nursing staff as a routine 
part of daily assessment of patient acuity (“QUADRAMED,” nursing quality indicators 
data). Because it was collected as part of the routine assessment and was used to 
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determine nurse staffing, there was incentive for accurate assessment and the 
information provided by the nurses was expected to reflect actual patient conditions. 
Prior to this project, the Department of Hospital Epidemiology at UNC Hospitals used 
the nursing assessment data to determine device-day denominators for their 
quarterly reported device-associated HAI infection rates. 
Table 2.  Source data for variables. 
Variable Description Source dataset 
Admission Date 
date patient admitted to 
hospital 
Hospital Infection Database,  
Physician Billing Data  
Ventilator Use Dates date ventilator in use Nursing Assesment 
Central Line Use Dates date central line in use Nursing Assessment 
Discharge Date 
date patient discharged from 
hospital Hospital Infection Database 
Infection Date date of infection Hospital Infection Database 
Infection Type 
type of infection (VAP, 
CLABSI) Hospital Infection Database 
Age age of patient at admission 
Hospital Infection Database,               
Physician Billing Data 
Sex gender of patient Physician Billing Data 
Race race of patient Physician Billing Data 
Ethnicity ethnicity of patient Physician Billing Data 
Service 
hospital service attending 
patient Physician Billing Data 
location 
location of patient (which ICU, 
which floor) 
Hospital Infection Database, 
Nursing Assessment, Physician 
Billing Data 
ICD-9 codes 
ICD-9 codes associated with 
patient at time of discharge Physician Billing Data 
 
Identification of infection 
 The UNC Hospitals Infection database was established in 1977 in the 
Department of Hospital Epidemiology. It included all HAI at UNC Hospitals. Infection 
control practitioners and nurses used criteria developed by the CDC to conduct 
infection control surveillance throughout the hospital.  Prior to inclusion of an 
infection in the database, it was reviewed by a nurse supervisor and a physician who 
specialized in infectious disease and critical care medicine.  Definitions for VAP and 
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CLABSI between 2002 and 2007 are below.   
Ventilator Associated Pneumonia (VAP) 
 The CDC definition for VAP stated that a physician diagnosis for pneumonia 
alone was not sufficient for nosocomial pneumonia. Signs and symptoms, radiology 
findings, and laboratory confirmation must also be presented. In the case of VAP, 
the patient had to meet criteria for pneumonia and have had the device in place to 
assist or control respiration continuously over the 48 hours prior to the onset of 
infection [1].  Thus, the patient must have a MV for at least 2 days to be considered 
at risk for VAP.  
Central line-Associated Blood-stream Infection (CLABSI) 
 The CDC definition for CLABSI stated that BSIs must either be laboratory 
confirmed or constitute clinical sepsis.  Laboratory-confirmed BSIs needed to have a 
recognized pathogen not linked to another infection site or signs of infection with a 
common skin contaminant culture [1].  At least one CL had to be present for at least 
24 hours (1 day) before the patient could have CLABSI.  
 Since multiple VAP and CLABSI could occur within one patient, one 
hospitalization, or even one device placement period, there could be multiple 
infections recorded per patient in the infection database.   
Selection Criteria 
 All patients at UNC Hospitals between 2002 and 2007 with documented use 
of a CL for at least one day or MV for at least two days while in the hospital were 
included in this study. Patients admitted with or acquiring infection within 24 hours of 
hospitalization for CL or 48 hours for MV were not considered to have a nosocomial 
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infection and were not included in analyses.  All other patients with these devices 
were included for analysis.  These criteria were congruent with CDC guidelines and 
UNC Hospitals HAI surveillance [1,2]. 
 The advantage of including all patients with one of these medical devices was 
that it provided information for ICU and floor patients and both adult and pediatric 
patients.  Many published studies are limited to ICU patients or report solely adult or 
pediatric infection rates.  Because we included all patients, we were able to provide 
a comparison across patient locations and ages.  We were also able to assess these 
as risk factors for device-associated infection. 
 We assessed a larger number of people who have devices placed over a 
longer calendar period than has previously been reported in the published literature. 
Thus, the number of infections seen was large and we were assured that we were 
analyzing trends in duration of device placement prior to infection rather than only 
monitoring an outbreak.  With this large amount of data, increases in infection rate 
were likely an actual increase, not a measure of statistical chance.  
B. Methods for proposed study 
Time at risk for VAP or CLABSI 
 The aims of this proposal focused on whether each patient’s duration of 
hospitalization or device duration should be incorporated into calculations of device-
associated HAI rates.  For this reason, time-at-risk was considered the “exposure.”  
We calculated multiple time-at risk variables for the analyses. 
 Dates of admission, device placement, discharge, and device removal were 
used to determine time-at-risk variables.  Date of infection was used in calculations 
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among patients who developed VAP or CLABSI. 
 Four calculations of exposure time were used as denominators in this study.  
“Patient-days” was the time from hospital admission to hospital discharge for all 
patients.  In Figure 2., patient-days was the time between ‘0’ and ‘d.’ “Device-days” 
was the time between device placement (‘a’ in Figure 2.) and device removal (‘c’).  
Acquiring infection did not necessitate removal of the device, and multiple infections 
per device placement were possible, so the CDC definitions did not make 
recommendations concerning excluding time with the device after infection occurred.  
Thus, “device-days” was the presumptive denominator in national surveillance of 
HAI infection rate calculations.  And, studies which utilized “patient-days” 
presumptively used the definition above as well. 
Figure 1.  Calculating time at risk 
 
 
 
 
 
 The other two exposure measures were truly for time-at-risk. “Patient-days-at-
risk” was the duration of time between hospital admission (‘0’) and infection (‘b’) for 
patients developing infection and the time between hospital admission and hospital 
discharge (‘d’) for patients not developing infection.  “Device-days-at risk” was the 
duration of time between device placement (‘a’) and infection for patients developing 
infection and the time between device placement and removal (‘c’) for those not 
developing infection. 
Hospital     Device                Device     Hospital 
Admission         Placement    Infection        Removal    Discharge 
     0   a          b   c  d 
 27 
Table 3. Description of exposed time variables 
Exposure time Description Calculation from Figure 2. 
Patient-days Time from admission to discharge Time d – Time 0 
Device-days Time from device placement to 
removal 
Time c – Time a 
Patient-days-at-
risk 
Time from admission to infection 
among infected and from admission 
to discharge among uninfected 
Time b – Time 0, if infected 
Time d – Time 0, if uninfected 
Device-days-at-
risk 
Time from device placement to 
infection among infected and from 
placement to removal among 
uninfected 
Time b – Time a, if infected 
Time c – Time a, if uninfected 
 
Exposure period 
 Dates of admission and discharge were obtained from physician billing data.  
Date(s) of infection diagnosis were documented in UNC Hospitals Infection 
Database after confirmation by an infection control nurse and doctor.  Dates of 
device placement and removal were determined based on dates nurses reported 
assessment of the devices as part of their daily routine care.  CL and MV placement 
were assumed to occur on the date of admission when the nursing assessment 
indicated presence of a CL or MV on that day.  When a CL or MV was first noted 
after the date of admission, we assumed it was placed one day prior to the nurse 
indicating device presence and counted the first date of assessment as the day after 
placement.  A one-day gap in CL use or two-day gap in MV use in the nursing 
assessment was considered to represent continuous use.  A gap of more than one 
day for CL or two days for MV was assumed to reflect removal and replacement of 
the devices.  We did this because not all nurses record quality indicators for every 
shift and because the one and two day periods were consistent with the CDC and 
UNC Hospitals time-line for device-associated infection surveillance definitions. 
Measurement characteristics 
 A patient could have both a MV and CLs placed during a hospitalization.  
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Each device could be placed on a different day and be used for a different amount of 
time. Each device could be associated with a separate infection event.  We analyzed 
VAP and CLABSI models separately.  A patient could have multiple VAP or CLABSI 
associated with a single device duration throughout hospitalization.  The main 
analyses assessed the first infection associated with each device.  Sensitivity 
analyses for both specific aims assessed similar models with multiple infections per 
device placement. 
 A patient could also have multiple CL placed at the same time during a 
hospitalization.  In our models, multiple CLs only contributed one device-day for 
each calendar-day.  We were unable to assess the effect of multiple lines versus a 
single CL or of different types of CL (e.g. single or triple lumen).  
 By definition, patients could not have a device-associated infection during the 
first 1-2 days of hospitalization or device placement.  Thus, we did not include this 
time in any of the models.   
Covariates - gender, race, ethnicity, and age 
 Gender, race/ethnicity, and age were obtained from the physician billing data 
for each patient. Gender was recorded as a dichotomous variable.  Race/ethnicity 
was categorized based on the information in the billing data and treated as an 
indicator variable in models.  Age on date of admission was recorded in years and 
included in models as a continuous covariate [3]. 
Covariates - location 
 Location of patient in the hospital was considered a time-dependent variable 
in this study.  Patient location was collected from the nursing assessment data for 
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each day of device placement and from the physician billing data for the remainder 
of the hospitalization.  A dichotomous ICU versus floor/step-down unit covariate was 
used for study analyses. 
Figure 2.  Changing service over time in hospital. 
 
 
 
 
 
 
 
Covariates - hospital service  
 The hospital service providing care to the patient was a time-dependent 
variable.  Starting hospital service was collected on date of admission from the 
physician billing data.  Dates for any change in services were also collected from the 
physician billing data. Change in service was converted from the date of change to 
the number of days since admission or device placement (depending on the 
exposure variable used). Thus, in Figure 2, time between 0 and x was assigned to 
the surgical service and time between x and d was assigned to the medical service. 
Covariates - comorbidities 
 Up to three ICD-9 codes for each hospitalization were recorded in the 
physician billing data. They were used to adjust for comorbid conditions.  Indicator 
variables were included for the following comorbidities: diabetes, cardiovascular 
complications, trauma, pulmonary complications (i.e. chronic obstructive pulmonary 
disease, asthma), acute respiratory distress syndrome (ARDS), sepsis, acute renal 
Hospital     Device                Device     Hospital 
Admission         Placement    Infection        Removal    Discharge 
     0   a  x          b    c  d 
surgical medical 
Date of service 
change 
Date of service 
change 
 30 
failure, and immune suppression (i.e. cancer, HIV, transplant) as indicated in 
previous literature [4-10]. 
Data analysis 
 
Specific Aim 1. Measuring changing rates of infection across duration of 
device placement 
 
 The first specific aim of this proposal was to describe and model how the 
rates of CLABSI varied across duration of time with CL and MV, respectively. The 
analysis for this aim consisted of three overarching steps. Each step was conducted 
separately for each device and two separate manuscripts were developed for 
CLABSI and VAP.  An overview of the steps included in this analysis is in Table 4. 
Table 4. Steps involved in analysis of Specific Aim 1. 
Step 
number 
Short Description Accomplished by: 
1.1 Clarify and describe changing 
rates* 
• Rates of infection conditional on continuing device 
duration and not having previous infection 
• Graphs 
• Life tables 
1.2 Model changing rates • Test for relationship between covariates and time to 
infection 
• Test for confounding 
• Test for time interactions 
• Discrete-time hazards regression 
1.3 Deterministic Sensitivity 
analyses 
• Multiple infections per device placement 
• Gap analysis 
• For CL, assess only placements not including date 
of admission 
* All rates for aim 1 used the device-days-at-risk time variable. 
 
 
Aim 1.1 Clarify and describe changing rates 
 Knowing the patterns of infection over time with the device and plotting the 
change in daily rate over time allows us to have a better understanding of when 
hospitalized patients get device-associated infections. Thus, the first step of aim 1 
was to clarify and describe the infection rate for each day with each device. 
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 An overall rate for VAP was determined by dividing the number of first VAP 
infections by the total number of ventilator-days prior to infection among all patients.  
An infection rate for each day with the device was then calculated by dividing the 
number of VAPs on that day (date of device placement was day 0) by the people 
with a ventilator on that day and without prior infection. The overall and changing 
rates of infection were plotted. Similar rates were calculated for CLABSI. 
 Life tables including the number of people with continuing device use and 
without prior infection, number of people with incident infection each day, rate of 
infection conditional on continuous device use, and rate of survival from device 
placement to each day were constructed.  Conditional infection rates and survival 
curves were graphed. 
 These initial graphs were difficult to interpret due to noise in the day-to-day 
infection rates across device duration.   Short time intervals were defined for 
subsequent analysis.  For CL, we estimated hazard and survival rates across 3-day 
periods throughout the first 21 days of insertion, weekly hazard rates were 
determined between days 22 and 56, and a single CLA-BSI rate was determined for 
subsequent duration.  For MV, we estimated hazard and survival rate across three-
day periods for the first 21 days, weekly hazard rate between 22 and 35 days, and a 
single VAP rate for all person-time greater than 36 days.  Rate of CLA-BSI across 
duration with CL and rate of VAP across duration with MV were estimated using 
lifetable methods and plotted with 95% confidence intervals. 
Aim 1.2 Model changing rates 
 Discrete-time hazards regression [11] was used for modeling because it 
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explicitly modeled the changing rates of CLABSI and VAP across duration of device 
placement and it allowed multiple time-dependent variables.  It also allowed the 
hazard function to have a previously unspecified shape [12].  We began with a 
model including only duration of device placement as the predictor of infection.  We 
then determined the extent of change in the rates of device-associated HAI while 
accounting for risk factors.  The covariates examined were: age, gender, 
race/ethnicity, comorbidities (as captured via ICD-9 codes), patient location, and 
hospital service. 
 A model containing all potential confounders was used to determine whether 
there were any time interactions.  All covariates were tested for interaction with time 
by multiplying the indicator variables for the covariate by the indicator variables for 
exposure time and including that in a new model.  An a priori α=0.05 for the 
interaction term or the likelihood ratio test between the two models was used to 
determine statistical significance for these interactions.  If hazard plots visually 
indicated a categorical interaction between a covariate and time, this categorical 
interaction was also assessed using an a priori α=0.05.   
 All covariates not interacting with time were included in the model as risk 
factors.  This process of model building allowed us to account for differences in the 
rate of infection across duration of device placement that were attributable to risk 
factors.  It also allowed us to model time as the “exposure.”  And, it allowed us to 
assess whether any variation in the rate of infection could be explained by changes 
in the patient population at risk across duration of device placement. 
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Aim 1.3 Deterministic sensitivity analyses 
 Two possible sources of bias warranted special consideration. The first was 
our method of determining duration of device placement.  Since we used nursing 
assessment data to get information on patients with devices, we assumed for the 
main analysis that a 1-2 day gap in device placement represented continuous use.  
In order to determine whether this assumption dramatically influenced our results, 
we assessed gaps of 1, 2, 5, and 7 days as continuous device placement.  
 The second source of bias was that CL use could occur outside the hospital.  
Thus, patients with CL assessment on the date of hospital admission may have had 
the CL for an unknown duration rather than starting an initial placement.  Thus, we 
also assessed the rate of CLABSI among only those patients without a CL 
assessment noted on the date of admission. 
 While device-days-at-risk was the denominator of interest, we also knew that 
multiple device-associated infections could occur within a single device placement.  
Thus, we conducted a sensitivity analysis to determine whether changes in infection 
rates across device duration were still present when multiple infections per 
placement were included in the analysis. 
Note about missing data 
 Missing data was minimal.  Missingness was no greater than 5% for any 
variable and no formal analysis plan for missing data was included in the study.  The 
number of placements in each model was kept as high as possible, thus the number 
of placements analyzed varies between models. 
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Specific Aim 2. Impact of denominator 
 The second aim of this proposal was to determine the impact of changing 
versus constant device exposure assessments for VAP and CLABSI infection rates 
among hospitalized patients and to determine whether the variation in rates 
remained important with different measures of exposed time (i.e. different 
denominator choices).  The analysis for this aim consisted of five steps. Each step 
was conducted separately for each device type, and a single manuscript was 
developed to present the results for VAP.  The results for CLABSI were similar and 
are presented in an abbreviated format.  An overview of the steps is presented in 
Table 5 (next page). 
Aim 2.1 Rates associated with devices 
 The second aim of this proposal focused more specifically on whether each 
patient’s exposure should be incorporated into calculations of rates of infection and 
to what extent measuring changing rates of infection over time provides new, 
meaningful information.  As a first step, we calculated the rates of infection at UNC 
Hospitals using the actual number of infections on each day and the number of 
exposed patients each day indicated by device exposure.  These ‘actual’ rates of 
infection were compared to constant rate and changing rate models.  Observed 
rates were calculated using each of the four denominators of exposure time.  Short 
definitions for these denominators are provided in Table 6.  
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Table 5.  Steps involve in analysis for Specific Aim 2 
Step 
number 
Short Description Accomplished by 
2.1 Determine daily rate of 
infection based on each of 
four options for exposed time 
• Calculate number of people contributing patient-time 
each day  
• Calculate daily rate of infection by dividing number 
of infections by patient-time for each time variable 
2.2 Determine unadjusted, 
constant rates of infection (for 
each denominator) 
• Divide total number of infections by total number of 
days patients exposed 
2.3 Model unadjusted changing 
rate over time (for each 
denominator) 
• Discrete-time hazards models  
2.4 Create tables and graphs 
comparing observed and 
model-based rates of 
infection 
• Develop one table for each denominator 
• Each table should include:  
o observed number of people contributing patient-
time each day;  
o observed infection rate each day;  
o discrete-time hazards model expected infection 
rate for each day;  
o error between model and observed daily infection 
rate;  
o difference between expected and observed 
number of infections;  
o error between constant rate and observed rate 
for each day;  
o difference between expected number of people 
from constant rate compared to observed rate of 
infection each day 
• Graph information from tables 
2.5 Develop constant rate and 
changing rate models 
adjusted for risk factors 
indicated in aim 1.  
• Poisson models for constant rate of infection 
adjusted for covariates indicated in aim 1 
• Discrete-time hazards models for changing rates of 
infection, adjusting for covariates indicated in aim 1 
• Develop tables for comparing these models to the 
observed rates of infection like those in aim 2.4 
 
 
 
Table 6.  Four exposure time calculations for rate denominators. 
Denominator for rate Exposure time calculation 
among infected 
Exposure time calculation 
among uninfected 
Patient-days time from admission to 
discharge 
time from admission to 
discharge 
Patient-days-at-risk time from admission to infection time from admission to 
discharge  
Device-days time from device placement to 
removal 
time from device placement to 
removal 
Device-days-at-risk time from device placement to 
infection 
time from device placement to 
removal 
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Aim 2.2 Unadjusted, constant infection rates 
 Unadjusted, constant rates of infection will be determined using a Poisson 
regression model including only the intercept.  This was equivalent to dividing the 
total number of infections associated with a device by the total number of exposed 
days for all patients.  Ninety-five percent confidence intervals were determined using 
the intercept parameter estimate and standard deviation from the model. 
! 
rate = e
"  
 The first 1-2 days (for CLABSI and VAP models, respectively) of 
hospitalization or device placement were not included in each persons total patient-
days or device-days calculations. Thus, the time when patients were not yet at risk 
for the infections was not included in the total number of days at risk. 
Aim 2.3 Unadjusted, changing rates over time 
 We also modeled the data allowing the rate of infection to change across the 
duration of exposure using discrete-time hazards analysis.  Models for each 
denominator including only the duration of exposure provided information about the 
expected rate of infection for each day.  This set of models allowed us to determine 
the differences between a changing rate of infection across duration exposed time 
compared to the constant rate models. 
 We conducted two discrete-time hazards analyses for each denominator.  
The first had time periods of longer length to allow for smoothing and visualization of 
underlying trends.  The second used shorter time periods, lengthening later time 
periods due to sparse data with longer duration of exposure.   
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 Hazard rates were calculated for each time interval using the associated, 
period-specific intercept (αn).   
! 
hazard
n
=
1
1+ e
("n )
 
 Typically, the hazard for a discrete time period is the conditional probability of 
an event that can only occur once per patient.  In our patient population, infection 
could occur multiple times in one person, one admission, or even during one device 
placement.  We used generalized estimating equations [13] to account for multiple 
admissions or device placements in one person and multiple infections per 
placement.  Because only a few device placements and admissions had more than 
one associated infection, we used an exchangeable correlation matrix, requiring only 
one parameter, but allowing for non-zero correlation between multiple device 
placements and infections in one person. 
Aim 2.4 Comparing actual and modeled rates 
 A table was created for each denominator option for comparison of the actual 
rate each day to the constant rate model and changing rate models of infection. 
Each table included information about the number of people with exposed time on 
that day (i.e. denominator) as well as the actual number and rate of infections on 
that day.  
 The rate from each of the models was multiplied by the number of patients 
continuing to contribute to the duration of device placement in order to calculate an 
expected number of infections for each day.  The modeled rates of infection were 
subtracted from the actual daily rate of infection for each day of exposure duration.  
The difference between the modeled and actual rate was squared and summed 
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across the duration of exposure to calculate the sum of squared error term for the 
model.  The standard deviation of the rate of infection was used to determine 95% 
confidence intervals.  Graphs comparing the numbers of expected and observed 
infections and infection rates were utilized to visually compare the calculation 
techniques.  Differences between the model-predicted and observed infection rates 
each day were plotted across the duration of exposure.  F-tests comparing the 
constant rate model to both the longer time interval discrete-time hazards model and 
the shorter time interval discrete-time hazards models and a F-test comparing the 
discrete-time hazards models were also used to determine whether models with 
fewer parameters had comparable fit to the observed incidence [14,15] with an a 
priori α=0.05 chosen to identify statistical significance.   
Aim 2.5 Adjusted model rates 
 Adjusted constant and changing rate models were also fit to the data for each 
of the four denominator choices using all covariates from Specific Aim 1.  These 
adjusted models allowed us to determine the extent to which the modeled constant 
and changing rates of infection could be explained by changes in the patient 
population at risk across duration exposure. 
 We also assessed constant and changing rate models for specific 
subpopulations of interest. Rates of pneumonia may vary across these different 
groups of patients as well as throughout the duration of device exposure.  Inclusion 
of these risk factors allowed us to assess whether the rate of infection across the 
duration of ventilation was independent of changes in risk factor distribution 
throughout time. 
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 Target populations were chosen to determine whether models performed 
differently for different groups of interest.  These five target groups were: patients 
over age 65, patients under age 18, patients in an intensive care unit (ICU), patients 
on a surgical service, and patients on an surgical service with a trauma diagnosis.   
 The constant rate models for each subpopulation were determined using the 
linear vector, including the intercept, from univariate regression of a Poisson model 
of the entire study population, to model the natural log of the constant rate among 
the target population.  Discrete-hazard models for the entire population were 
constructed with the addition of a dichotomous covariate for inclusion in the target 
population.  The conditional rate for each time interval for the target population was 
then calculated and compared to the actual daily rate of infection for that group. 
 Tables and graphs similar to those described in aim 2.4 were created for 
these target subgroups using the adjusted models.  Graphs and F-tests were used 
to compare the models in each subgroup. 
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 V. RESULTS:  CHANGING RATE OF BLOOD-STREAM INFECTION ACROSS 
DURATION OF CENTRAL VENOUS ACCESS 
A. Introduction  
 
 About 5 million central venous catheters or “central lines” are inserted every 
year in the United States [1].  Patients with central lines (CL) represent 87% of all 
primary blood-stream infections [1].  Reported CLABSI rates range 0.7 to 18.5 per 
1000 CL-days [1,3-9].  Patients with CL-associated bloodstream infections (CLABSI) 
are at increased risk of dying in hospitals with nearly 27,000 attributable annual 
deaths [2].  
 While rates of CLABSI are widely reported in the literature, most studies 
assume a constant infection rate throughout duration of CL use.  Changes in the rate 
of CLABSI throughout CL duration have not been well documented.  Further, few 
previous studies have used multivariate analysis to adjust for covariates.  
 The primary objective of this study was to determine whether and how the 
rate of CLABSI changed throughout the duration of CL use.  A secondary objective 
was to identify risk factors for CLABSI and to assess whether any variation in the 
rate of infection could be explained by changes in the patient population at risk 
across duration of CL placement. 
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B. Methods 
Participants 
 This study includes 27,397 individuals who were hospitalized at UNC 
Hospitals between 1 January, 2002 and 31 December, 2007 and had at least one 
CL inserted for one or more days during their hospitalization.  
 Data were collected as part of usual hospital care in UNC Hospitals.  
Information about whether patients had a CL and hospital location was collected by 
the nursing staff as a routine part of their daily assessment.  Demographic, hospital 
service, and diagnosis data were extracted from administrative physician billing 
records.  Infection data were retrieved from the standardized surveillance records of 
the Department of Hospital Epidemiology.  Data from the three sources were 
combined using medical record numbers, dates of admission and CL use. 
Outcome 
 Infection control surveillance was conducted by five infection control 
professionals supervised by two full-time faculty.  Comprehensive hospital-wide 
surveillance was performed using definitions developed by the Centers for Disease 
Control and Prevention [10].  CLABSI was defined as any bloodstream infection 
occurring at least one day after CL placement through the first day after CL removal 
with no other explanation for the infection.  
Time at risk 
 CL placement was assumed to occur on the date of admission if the nursing 
assessment indicated presence of a CL on that day.  When a CL was first noted 
after the date of admission, we assumed it was placed one day prior to the nurse 
 44 
indicating its presence and counted the first date of assessment as the day after 
placement.  A one-day gap in CL use from the nursing assessment was considered 
to represent continuous use.  A gap of more than one day was assumed to reflect 
removal of all CLs and subsequent insertion of one or more new lines. 
Covariates 
 Variables collected for this study included: dates of admission(s) and 
discharge(s), dates when the patient had at least one CL, date of onset of 
CLABSI(s), gender, race, location of patient within hospital, service to which patient 
was assigned, and up to three ICD-9 diagnosis codes for each patient.  Race was 
defined as White, Black, Hispanic, and other or non-specified race.  Age was 
determined at time of admission and centered at 50 years for analysis.  Patient 
location was defined as in an intensive care unit (ICU) versus on a floor or step-
down unit.  Hospital service was collapsed into broad categories of adult medical, 
adult surgical, pediatric, or other service (including rehabilitation, 
obstetrics/gynecology, etc.). 
 Because a patient may move or change service during the course of one CL 
placement, we represented patient location and hospital service as time dependent 
variables across CL duration.  When a patient changed location or service, the first 
location or service continued to contribute time toward CLABSI for one day after the 
move.  
 Up to three ICD-9 diagnosis codes were used to determine patient 
comorbidities during each admission.  We focused on the eight comorbidities that 
have previously been associated with device-associated nosocomial infection [11-
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17]:  diabetes, cardiovascular complications, trauma, pulmonary complications 
(COPD and asthma), acute respiratory distress syndrome, sepsis, acute renal 
failure, and immune suppression (cancer, HIV, and transplant patients).   
Statistical analysis 
 The data were analyzed using survival (time-to-event) methods.  The number 
of patients at risk decreased with increasing CL duration, with relatively few patients 
having line(s) continuously inserted for more than two months.  Thus later time 
periods had more imprecision, and accordingly we estimated hazard and survival 
rates across 3-day periods throughout the first 21 days of insertion, weekly hazard 
rates were determined between days 22 and 56, and a single CLABSI rate was 
determined for subsequent duration.  Rate of CLABSI across duration with CL was 
estimated using lifetable methods and plotted with 95% confidence intervals.  
 We used discrete-time hazards analysis [18] to model rate of CLABSI across 
duration of CL placement and to identify risk factors.  We accounted for the fact that 
a single patient may have multiple CL placements using generalized estimating 
equations [19].  Time intervals in this analysis were the same as those in the life 
table analysis and models were censored after 56 days of CL placement.  Rates of 
CLABSI were calculated from the models using the following formula: 
! 
h
t
=
1
1+ e
"#
  
where 
! 
"  represents the log odds of the hazard rate for a given time interval in the 
model.  
 Gender, race/ethnicity, age, comorbidities, hospital service, and patient 
location were each individually added to the life tables and discrete-time hazard 
models to assess their potential as risk factors.  Visual inspection of lifetable plots 
 46 
was used to assess potential interactions with time.  Time interactions were deemed 
significant if a Wald or likelihood ratio test p-value was less than 0.05 when 
comparing models with and without the interaction term(s). 
 A discrete-hazards model including all covariates and any significant time 
interactions was used to determine adjusted hazard rates and 95% confidence 
intervals for each time interval.  Mutually adjusted odds ratios and 95% confidence 
intervals for potential risk factors were also calculated from this model. 
 Lifetable and discrete-time hazards analyses were repeated for rate of all 
CLABSI including multiple (repeated) infections across CL placement, again 
adjusting for multiple durations of CL use within patients and potential risk factors.  
C. Results 
Demographics 
 During the study period, January 1, 2002 to December 31, 2007, there were 
125,594 patients admitted to UNC Hospitals.  Of those patients, 27,397 (21.8%) had 
at least one CL for at least one day.  Forty-eight percent were female, 60.0% were 
White, and 29.6% were Black (Table 7). The average age on the date of admission 
was 43 (standard deviation (sd) 25) years.  Overall, 21.2% of admissions were 
individuals under 18 years of age. 
 Among these 27,397 people, 39% had more than one period of CL use for a 
total of 57,687 placements (Table 8).  The average number of CL durations per 
person was 2.1 (sd 2.6).  The median CL duration was 7 days (interquartile range 
(IQR) 2-8 days).   
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 Thirty-eight percent of CL placements were in patients with at least one 
comorbidity.  The most frequent recorded comorbidities were immunodeficiency 
(14.5%), acute respiratory distress syndrome (10.6%) and cardiovascular 
complications (6.4%).  Thirty percent of CL placements began in the ICU.  Thirty 
percent of CL placements began on an adult surgical service, 42% began on an 
adult medical service, and 17% began on a pediatric service.  Only 3% had service 
changes and less than 1% had location changes between the ICU and floor/step-
down unit while maintaining CL placement.  
 
Table 7. Characteristics of patients with central lines at UNC Hospitals in 2002-2007. 
  
Number of 
people % 
Number with 
CLABSI* % 
Risk of CLABSI 
per 100 people 
(95% CI) 
Total 27397  1231  4.5 (4.2, 4.7) 
Gender      
  Male 14167 51.7 540 43.9 3.8 (3.5, 4.1) 
  Female 13230 48.3 691 56.1 5.2 (4.8, 5.6) 
Race      
  White 16425 60.0 631 51.3 3.8 (3.5, 4.1) 
  Black 8115 29.6 452 36.7 5.6 (5.1, 6.1) 
  Hispanic 1101 4.0 52 4.2 4.7 (3.5, 6.0) 
  Other race 1752 6.4 96 7.8 5.5 (4.4, 6.5) 
People with central lines by year     
  2002 4656 17.0 223 18.1 4.8 (4.2, 5.4) 
  2003 5058 18.5 250 20.3 4.9 (4.3, 5.5) 
  2004 5482 20.0 221 18.0 4.0 (3.5, 4.6) 
  2005 5714 20.9 211 17.1 3.7 (3.2, 4.2) 
  2006 5978 21.8 190 15.4 3.2 (2.7, 3.6) 
  2007 6197 22.6 173 14.1 2.8 (2.4, 3.2) 
Admissions per 
person (sd*)  1.7 (2.1)  3.0 (4.5)   
Central line 
placements per 
person (sd) 2.1 (2.6)  4.5 (5.4)   
Combined duration 
with central line per 
person (sd) 15 (27)   63 (67)     
*CLABSI: central line-associated blood-stream infection; sd: standard deviation. 
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Table 8. Characteristics of patients by total number of central line placements at UNC Hospitals 
in 2002-2007. 
  
Number of CL* 
placements 
% of 
placements 
Days with 
CL 
Number of 
CLABSI* 
Total 57,687  414,887 1355 
Gender     
  Male 29,719 51.5 219,662 769 
  Female 27,966 48.5 195,204 586 
Race     
  White 33,420 57.9 238,263 676 
  Black 18,639 32.3 131,293 503 
  Hispanic 1,819 3.2 14,463 61 
  Other race 3,809 6.6 30,868 115 
Age (sd) 43 (25)   37 (27) 
Comorbidities     
  Average number (sd) 0.41 (0.56)   0.47 (0.60) 
  Diabetes 547 0.9 2,735 4 
  Cardiovascular  
    Complications 3,667 6.4 21,250 47 
  Trauma 2,455 4.3 21,903 80 
  Pulmonary Complications 873 1.5 4,966 10 
  Acute Respiratory 
    Distress Syndrome 6,099 10.6 71,918 316 
  Sepsis 122 0.2 1,054 1 
  Acute Renal Failure 1,651 2.9 3,284 56 
  Immunodeficiency 8,369 14.5 49,986 123 
Total number comorbidities     
  0 35,977 62.4 249,505 792 
  1 19,681 34.1 144,301 492 
  2 1,985 3.4 20,448 68 
  3 44 0.1 633 3 
Beginning location     
  ICU 17,041 29.5 161,787 660 
  Floor or step-down unit 40,640 70.4 253,037 695 
  Number CL placements  
     with at least one change 4 0.0 40 0 
Beginning Hospital Service     
  Medicine 24,309 42.1 154,153 618 
  Surgery 17,490 30.3 128,079 648 
  Pediatric 9,825 17.0 97,119 23 
  Other 3,671 6.4 17,042 66 
  Number CL placements 
    with at least one change 
1,619 2.8 27,860 101 
Median duration of CL  
  placement (IQR) 
7 (2, 8)   30 (12, 37) 
*CL: central line; CLABSI: central line-associated blood-stream infection; CI: confidence interval; sd: 
standard deviation; IQR: interquartile range. 
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Infection rate 
 A total of 1,469 infections occurred in 4.5% of all patients and in 2.3% of all 
CL placements resulting in 5.36 CLABSI (95% Confidence interval (CI) (5.10, 5.63)) 
per 100 patients admitted and 3.27 CLABSI per 1000 CL-days (95% CI 3.09, 3.44 
per 1000 CL-days) (Table 9).  Among the 1,355 CL placements resulting in at least 
one CLABSI, 43% were in females, 50% in Whites, and 37% in Blacks (Table 8).  
Comorbidities were listed among ICD-9 codes in 42% of CL placements; the most 
frequent of which were acute respiratory distress syndrome, immunodeficiency, and 
trauma.  Forty-nine percent were admitted to an ICU and 48% to adult surgical 
service.  The median number of days before infection was 9 (IQR 5-17) and the 
median total time with CL placement resulting in at least one infection was 21 (IQR: 
12-37) days.   
Time-to-infection analysis 
 Unadjusted life table estimates for time to CLABSI are shown in Table 10.  
The rate of infection rose steadily through the first two weeks following placement, 
declined steadily over weeks three and four, and then increased slowly with 
additional time.    
 The number of first infections peaked during days 4-6 for a total of 270 
CLABSI.  Second infections began occurring at the end of the first week.   Nearly 
50% of first CLABSI occurred by the end of day 9, and over 75% of first infections by 
day 18.  Accounting for multiple infections, 50% occurred by the twelfth day and 75% 
by day 21.   
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Table 9. Risk and rate of CLABSI by total number of central line placements at UNC  
Hospitals in 2002-2007.  
  
CLABSI* risk per 100 
placements (95%CI*) 
CLABSI rate per 1000 
CL-days (95%CI) 
Total 2.3 (2.2, 2.5) 3.27 (3.09, 3.44) 
Gender   
  Male 2.6 (2.4, 2.8) 3.50 (3.25, 3.75) 
  Female 2.1 (1.9, 2.3) 3.00 (2.76, 3.24) 
Race   
  White 2.0 (1.9, 2.2) 2.84 (2.62, 3.05) 
  Black 2.7 (2.5, 2.9) 3.83 (3.50, 4.17) 
  Hispanic 3.4 (2.5, 4.2) 4.22 (3.16, 5.27) 
  Other race 3.0 (2.5, 3.6) 3.73 (3.05, 4.41) 
Comorbidities   
  Diabetes 0.7 (0.0, 1.4) 1.46 (0.03, 2.89) 
  Cardiovascular  
    Complications 1.3 (0.9, 1.6) 2.21 (1.58, 2.84) 
  Trauma 3.3 (2.6, 4.0) 3.65 (2.85, 4.45) 
  Pulmonary Complications 1.1 (0.4, 1.9) 2.01 (0.77, 3.26) 
  Acute Respiratory 
    Distress Syndrome 5.2 (4.6, 5.7) 4.39 (3.91, 4.88) 
  Sepsis 0.8 (0.0, 2.4) 0.95 (0.00, 2.81) 
  Acute Renal Failure 3.4 (2.5, 4.3) 17.05 (12.62, 21.48) 
  Immunodeficiency 1.5 (1.2, 1.7) 2.46 (2.03, 2.90) 
Total number comorbidities   
  0 2.2 (2.0, 2.4) 3.17 (2.95, 3.40) 
  1 2.5 (2.3, 2.7) 3.41 (3.11, 3.71) 
  2 3.4 (2.6, 4.2) 3.33 (2.54, 4.11) 
  3 6.8 (0.0, 14.3) 4.74 (0.00, 10.09) 
Beginning location   
  ICU 3.9 (3.6, 4.2) 4.08 (3.77, 4.39) 
  Floor or step-down unit 1.7 (1.6, 1.8) 2.75 (2.54, 2.95) 
Beginning Hospital Service   
  Medicine 2.5 (2.3, 2.7) 4.01 (3.69, 4.32) 
  Surgery 3.7 (3.4, 4.0) 5.06 (4.67, 5.45) 
  Pediatric 0.2 (0.1, 0.3) 0.24 (0.14, 0.33) 
  Other 1.8 (1.4, 2.2) 3.87 (2.94, 4.81) 
  CL placements with at  
   least one change in  
   location 
6.2 (5.1, 7.4) 3.63 (2.92, 4.33) 
*CLABSI: central line-associated blood-stream infection; CI: confidence interval; CL: 
central line. 
 
Modeling 
 Discrete-time hazards models were limited to the first 2 months (56 days) of 
CL placement.  Results from the unadjusted discrete-time hazards model yielded the 
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same trends as found in life table analysis and indicate that the rate of CLABSI 
varies across CL duration (Figure 3).  There was a general trend of increasing rate 
across time with CL, but rates were lower at the end of the third week and during the 
fourth week than in periods before and after.  
Table 10.  Life table for CLABSI* at UNC Hospitals during 2002-2007. 
Cumulative 
duration of 
CL* 
placement 
(days) 
Number of 
placements 
without 
CLABSI at 
beginning of 
interval 
CLABS
I during 
interval 
Proportion   
(per 1000) 
with CLABSI 
during 
interval 
95% 
Confidence 
Interval 
Proportion  
without 
CLABSI at 
end of 
interval 
Standard 
Error 
1-3 57687 236 1.60 (1.39, 1.80) 1.00   
4-6 30635 270 3.54 (3.12, 3.97) 0.99 0.001 
7-9 17288 193 4.29 (3.69, 4.89) 0.98 0.001 
10-12 11350 150 4.92 (4.14, 5.71) 0.96 0.001 
13-15 8109 111 5.04 (4.10, 5.97) 0.95 0.002 
16-18 5974 83 5.07 (3.99, 6.16) 0.94 0.002 
19-21 4528 52 4.19 (3.05, 5.32) 0.93 0.003 
22-28 3427 78 4.12 (3.21, 5.03) 0.90 0.004 
29-35 1910 51 4.76 (3.46, 6.06) 0.88 0.005 
36-42 1124 35 5.32 (3.56, 7.08) 0.85 0.007 
43-49 725 24 5.58 (3.35, 7.81) 0.83 0.009 
50-56 472 13 4.62 (2.12, 7.13) 0.80 0.010 
57+ 332 59 7.57 (5.64, 9.49) 0.66 0.020 
*CLABSI: central line-associated blood-stream infection; CL: central line. 
 
Thus, the constant rate was an overestimate early on and an underestimate with 
longer duration (Figure 4).  Peak modeled infection rate (5.07 CLABSI (95% CI 4.09, 
6.28) per 1000 CL-days) occurred 16-18 days post-CL placement with another spike 
during the seventh week (5.57 per 1000 CL-days (95% CI 3.73, 8.30)).  Adjusting for 
year of CL placement did not alter the trends seen with duration of CL placement. 
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Figure 3.  Changing and constant rate of central line associated blood-stream 
infections over duration of central line placement (with 95% confidence intervals for 
changing rate). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
constant rate 
changing rate 
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Figure 4. Cumulative incidence of central line-associated blood-stream infection 
across duration of central line placement. 
 
 
Unadjusted risk factor assessment 
 Initially, we conducted univariate analyses in which potential risk factors were 
added to discrete-time hazard models individually to assess the effect on rate of 
CLABSI throughout CL placement (Table 11).  Compared to White patients, Blacks 
(OR 1.39, 95% CI 1.23, 1.56), Hispanics (OR 1.31, 95% CI 1.04, 1.65), and other 
races (OR 1.38, 95% CI 1.10, 1.73) had increased rate of CLABSI.  Patients located 
in the ICU (OR 1.41, 95% CI 1.27, 1.58) or on a surgical (OR 1.20, 95% CI 1.05, 
1.37) or pediatric service (OR 1.10 (95% CI 0.95, 1.26) also had increased CLABSI 
rates compared with patients on the floor/step-down unit or on a medical service.  
Increasing age was not associated with increased CLABSI (OR per 10 year increase 
0.99, 95% CI 0.97, 1.01).  Cardiovascular complications (OR 0.72, 95% CI 0.53, 
constant rate 
changing rate 
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0.97) and immunodeficiency (OR 0.74, 95% CI 0.61, 0.89) were associated with 
decreased rate of CLABSI while acute respiratory distress syndrome (OR 1.35, 95% 
CI 1.18, 1.54) and acute renal failure (OR 1.32, 95% CI 1.01, 1.74) increased 
CLABSI rate.   There were too few CLABSI among patients with diabetes, 
pulmonary complications, and sepsis to assess these as potential risk factors in 
discrete-time hazard models. 
Table 11.  Odds ratios for risk factors for CLABSI*.  
  
Univariate OR* (95% 
CI) 
Fully adjusted OR (95% 
CI) 
Gender   
  Female Ref* ref 
  Male < 7 days 1.36 (1.16, 1.58) 1.32 (1.13, 1.55) 
  Male > 7 days 1.03 (0.89, 1.19) 0.99 (0.85, 1.15) 
Race   
  White ref ref 
  Black 1.39 (1.23, 1.56) 1.36 (1.21, 1.54) 
  Hispanic 1.31 (1.04, 1.65) 1.07 (0.83, 1.40) 
  Other race 1.38 (1.10, 1.73) 1.31 (1.03, 1.67) 
Age   
  50 years old ref ref 
  per 10 year increase 0.99 (0.97, 1.01) 1.00 (0.96, 1.04) 
Initial patient location   
  Floor or step-down unit ref ref 
  ICU 1.41 (1.27, 1.58) 1.34 (1.19, 1.52) 
Initial hospital service   
  Medicine ref ref 
  Surgery  1.20 (1.05, 1.37) 1.15 (1.00, 1.33) 
  Pediatrics 1.10 (0.95, 1.26) 0.94 (0.75, 1.18) 
  Other 0.44 (0.28, 0.67) 0.49 (0.31, 0.75) 
Comorbidities^   
  Cardiovascular complications 0.72 (0.53, 0.97) 0.64 (0.47, 0.88) 
  Trauma 1.17 (0.92, 1.48) 1.01 (0.78, 1.31) 
  Acute respiratory distress syndrome 1.35 (1.18, 1.54) 1.12 (0.97, 1.30) 
  Acute renal failure 1.32 (1.01, 1.74) 1.27 (0.96, 1.68) 
  Immunodeficiency 0.74 (0.61, 0.89) 0.84 (0.69, 1.03) 
*CLABSI: central line-associated blood-stream infection; OR: odds ratio; CI: confidence 
interval; ref: reference group. 
^Referent for each comorbidity is all patients without that comorbidity. 
 
 Averaged across all time intervals, males had 17% higher odds of CLABSI 
compared to females (95% CI 1.04, 1.31).  But, the effect of gender differed across 
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time (Figure 5), with males having 36% greater CLABSI rate in the first week of CL 
placement (OR 1.36, 95% CI 1.16, 1.58) but similar to females thereafter (OR 1.03, 
95% CI 0.89, 1.19).  Adjusted models included separate terms for the effect of 
gender through the seventh day and after seven days with a CL.   
Figure 5.  Rate of central line associated blood-stream infections over time for men 
and women (with 95% confidence intervals). 
  
Full model adjusted for all covariates 
Effect of time 
 The overall trends across CL duration remained similar to the unadjusted 
model (Figure 5).  Rate of CLABSI increased across the first 2 weeks, decreased 
over the third and fourth weeks, and increased slightly with subsequent CL duration.  
The rate of CLABSI among 50 year-old white women located on a floor, medical 
service, and with no noted comorbidities (i.e, the baseline group, with all covariates 
women 
men 
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at the reference level) increased over the first week to 2.39 (95% CI 1.76, 3.25) per 
1000 CL-days and in the second week to 3.07 CLABSI per 1000 CL-days.  CLABSI 
decreased in the third and fourth weeks to a minimum of 1.56 (95% CI 0.72, 3.37) on 
day 24, and increased with additional duration.  Rate of CLABSI in other groups 
followed similar patterns of increasing and decreasing over time, but were higher or 
lower based on the odds of the covariate patterns.  For instance, the rate of CLABSI 
on the sixth day after placement among 50 year-old Black men in the ICU, surgical 
service, and who had a trauma diagnosis was 7.99 (95% CI 5.25, 10.74) per 1000 
CL-days.  The low-point on day 24 was 3.75 (95% CI 1.69, 8.30) per 1000 CL-days.  
Adjusted risk factor assessment 
 Adjusting for all other covariates and the effects of time, the rate of CLABSI 
among Black patients was 36% higher than among white patients (OR 1.36, 95% CI 
1.21, 1.54) (Table 11).  Hispanic patients had similar CLABSI rate across CL 
placement compared to whites (OR: 1.07, 95% CI 0.83, 1.40).  Patients in ICU had 
28% higher CLABSI rate (OR 1.34, 95% CI 1.19, 1.52) compared to patients located 
on a floor or step-down unit. CLABSI did not increase with increasing age (OR per 
decade 1.00, 95% CI 0.96, 1.04). Surgical patients had increased CLABSI across 
duration of CL placement (OR 1.15, 95% CI 1.00, 1.33) while pediatric patients were 
similar to medical patients (OR 0.94, 95% CI 0.75, 1.18).  Cardiovascular 
complications were associated with lower CLABSI rate (OR 0.64, 95% CI 0.47, 
0.88), and other comorbidities were associated with no change or slightly increased 
CLABSI rate.  
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D. Discussion 
 The rate of CLABSI was higher during the second week and early in the third 
week after initial CL placement.  The overall peak in the rate of CLABSI was on days 
16-18.  The increase in CLABSI over the first two weeks, then decrease after 18 
days to a lower infection rate on days 22-28 mimics the change in the rate of all 
nosocomial infections over duration of hospitalization found by Saviteer, et al. [20].  
In addition, our study provides information that the rate of CLABSI across duration 
with CL continues to fluctuate when adjusting for risk factors.   
 Identified risk factors for CLABSI include severity and type of underlying 
illness [10].  Gender, race, age, patient location (ICU vs floor), and hospital service 
have not been well studied as potential confounders in CLABSI, but have been 
identified as risk factors in ventilator-associated pneumonia, another device-
associated infection [11, 15, 17, 21-28].  Between 2002 and 2007, we found that the 
rate of CLABSI at UNC Hospitals changed throughout patients’ duration of CL use 
and varied by gender, race, comorbidities, location within hospital, and hospital 
service. 
 The changing CLABSI rate across time was lower than the constant rate over 
the first three days and higher after days 4-6.  Since 50% of CL placements last 
fewer than 6 days, lower rates during this time period decrease the overall constant 
rate.  We do not know whether these patients who had at least one CL for less than 
6 days without getting an infection were more or less healthy than those who 
continued use of CL(s) for more than 6 days.  Patients who were more healthy may 
have needed a CL for a shorter period of time, and because they were healthier 
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would have been less likely to have an infection during their time with a CL.  Patients 
who were less healthy were at greater risk for other, more severe competing risks, 
such as death.  One difficulty in interpreting our results is that patients who were 
more likely to die than to get CLABSI may look similar in our data to patients who 
were healthier and thus more likely to have the CL removed quickly.  Research 
including information on mortality and other competing risks would help parse out 
the differences concerning the amount of time healthier and sicker patients use CLs.  
 We only included one hospital in this analysis.  We were also unable to 
assess type of line (i.e. single or triple lumen), body location of the line (i.e. jugular or 
subclavian), adherence to aseptic technique, and whether antimicrobial impregnated 
lines were used.  All of these factors may influence CLABSI rate; but practices are 
standardized across this hospital and would not play a role in infections across CL 
duration or by service.  Thus, we expect that the variation in CLABSI throughout CL 
duration would be seen at other facilities as well. 
 An assumption of our data was considering a gap of more than one day to 
represent removal and placing new CL(s), so we conducted a separate analysis 
repeating the life table and discrete-time hazard modeling with a two-day gap in CL 
data representing the same CL.  This analysis yielded similar results, with an 
increase in CLABSI over the first week, relatively stable estimate in the second 
week, peak in infection rate early then decreasing throughout the third week, and a 
slow increase throughout remaining time with a CL.  
 Another concern with our data was that we were unable to determine whether 
patients who had CL at the time of admission (i.e. day zero) came to the hospital 
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with CL or had one (or more) inserted on that day.  We conducted a subset analysis 
including only patients without CL at admission and found the same trend of 
increasing CLABSI to the beginning of the third week then a drop in the rate through 
the fourth week and slight increase with subsequent CL duration. 
E. Conclusions 
 Central line-associated blood-stream infections (CLABSI) are an important 
cause of morbidity and mortality in hospitalized treatments, accounting for 14% of all 
healthcare-associated infections and over 30% of nosocomial infection-related 
mortality in the United States [2].  Duration of CL placement does appear to 
influence the risk of CLABSI for a patient.  Gender, race, age, patient location, 
hospital service, and comorbidities change the risk of infection.  Being aware of who 
is at increased risk of infection, monitoring patients closely throughout hospitalization 
and timing interventions and surveillance appropriately could decrease the rate of 
CLABSI among patients with CLs. 
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 VI. RESULTS:  CHANGING RATE OF VENTILATOR-ASSOCIATED PNEUMONIA 
THROUGHOUT DURATION OF MECHANICAL VENTILATION 
A. Introduction  
 Over 200,000 cases of ventilator-associated pneumonia (VAP) occur annually 
in the United States [1-2].  The risk of VAP during hospitalization is 5-28%.  
Reported rates of VAP in hospitalized patients range from zero to 57.6 per 1000 
ventilator-days [1, 3-21].  Hospitals reporting to the Centers for Disease Control and 
Prevention’s National Healthcare Safety Network have pooled mean rates from 2.1 
per 1000 ventilator-days among pediatric intensive care patients to 10.7 per 1000 
ventilator-days among burn unit patients [22]. 
 There is some evidence that the risk of VAP varies across the duration of 
ventilation. In a study of all nosocomial infections at University of North Carolina 
(UNC) Hospitals, rates of infection, measured in three-day increments, increased 
from days 2-4 to days 14-16, then decreased to day 23 of hospitalization [23].  In 
one study of VAP, 3% of patients contracted pneumonia each day in the first week, 
2% per day in the second week and 1% per day in subsequent weeks [24-25].  
Another study reported an increase in VAP over the first 10 days in an intensive care 
unit (ICU) and then a decrease and plateau after 20 days in the ICU [10].  However, 
these studies present data from Canada, Turkey, and before 1985 in the United 
States, and were of small size. 
 Risk factors for VAP have been identified [4-5,7,9-10,17,24,26-29], but 
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infection rates in previous studies were not adjusted for the presence of these risk 
factors.  Rates of pneumonia likely vary across these different groups of patients as 
well as throughout the duration of mechanical ventilation.  Adjusting for risk factors 
allows us to determine whether the rate VAP differs across the duration of ventilation 
independent of changes in risk factor distribution over that time period. 
 Our objective was to determine if the rate of VAP changes across duration of 
mechanical ventilator use and if variation in the rate is explained by changes in the 
patient population at risk of infection throughout that time.  A secondary objective 
was to provide further evidence to clarify risk factors for VAP.  
B. Methods 
Participants 
 This study included 11,041 patients at UNC Hospitals between 1 January, 
2002 and 31 December, 2007 who had a mechanical ventilator (including both 
patients with endotracheal tubes and/or tracheostomy) for at least two days.  
 Data were collected as part of usual care at UNC Hospitals.  Information 
about ventilator use, central venous catheter use, and location was collected via the 
nursing staff as part of a daily assessment of patient severity.  Data regarding 
patient demographics, hospital service, and comorbid diagnoses were obtained via 
administrative physician billing records.  Infection data were retrieved from 
nosocomial infection surveillance records of the Department of Hospital 
Epidemiology. Data from the three sources were combined using medical record 
numbers, and dates of admission, ventilator use, and discharge. 
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Time at risk 
 If the nursing assessment indicated presence of a ventilator on the date of 
admission, we assumed ventilator placement occurred on that date.  Otherwise, if 
ventilation was first noted after the date of admission, we assumed that the ventilator 
was placed on the day prior to the nurse indicating its presence during his or her 
assessment.  Per UNC Hospitals operational definition, we did not classify 
pneumonia in the first two days as VAP and considered patients at risk of VAP for 
two days after ventilator removal.  We also assumed continuous use of ventilation 
for gaps of up to two days in the nursing assessment.  Gaps of more than two days 
were considered to represent removal and reinsertion of the ventilator. 
Outcome assessment 
 Infection control surveillance was conducted by five infection control 
professionals supervised by two full-time faculty.  Comprehensive hospital-wide 
surveillance was performed using definitions developed by the Centers for Disease 
Control and Prevention [30-31].  
Covariates 
 Variables collected for this study included: dates of admission(s) and 
discharge(s), dates of mechanical ventilation, dates of concurrent central venous 
catheterization, date of onset of infection(s), gender, race/ethnicity, patient location, 
hospital service, and up to three ICD-9 diagnosis codes for each patient.  
Race/ethnicity was defined as White, Black, Hispanic, and other or non-specified 
race.  Age was determined at time of admission and centered at 50 years for 
analysis.  
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 Patient location was defined as in an intensive care unit (ICU) versus on a 
step-down unit or floor.  Hospital service was collapsed into broad categories of 
medical, surgical, or pediatric service.  Patients not on a medical, surgical, or 
pediatric service (e.g. psychiatric services) were not included in the analysis.  
Because a patient may move or change service during the course of one ventilator 
use, patient location and hospital service were represented as time dependent 
variables. If a patient changed location or service during an admission, VAP was 
attributed to the original location or service for two days after the move.  
 Up to three ICD-9 diagnosis codes were used to identify patient comorbidities 
during each admission.  We focused on those that have previously been associated 
with device-associated nosocomial infection [4, 7, 9, 26-29]:  diabetes, 
cardiovascular complications, trauma, pulmonary complications (COPD and 
asthma), acute respiratory distress syndrome, sepsis, acute renal failure, and 
immune suppression (cancer, HIV, and transplant patients).   
Statistical analysis 
 The data were analyzed using survival (time-to-event) methods.  The number 
of patients at risk decreased with increasing ventilator duration, with relatively few 
patients ventilated continuously for more than 35 days.  Thus, since later time 
periods had fewer events and greater imprecision, we estimated hazard and survival 
rate across three-day periods for the first 21 days, weekly hazard rate between 22 
and 35 days, and a single VAP rate for all person-time greater than 36 days.  Rates 
of VAP across duration of ventilation and associated 95% confidence intervals were 
estimated using life table methods. 
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 We used discrete-time hazards analysis [32] to model rate of first VAP across 
duration of ventilation and to identify risk factors.  We accounted for the fact that a 
single patient might have multiple ventilator placements using generalized estimating 
equations [33].  Time intervals in the discrete-time hazards analysis were the same 
as those in the life table analysis and models were censored after 35 days of 
ventilation.  
 Gender, race/ethnicity, age, comorbidities, hospital service, and patient 
location were each individually added to the life tables and discrete-time hazard 
models to assess their potential as risk factors.  Visual inspection of life table plots 
was used to assess potential interactions with time.  Time interactions were deemed 
significant if a Wald or likelihood ratio test p-value was less than 0.05 when 
comparing models with and without the interaction term(s). 
 A discrete-hazards model including all covariates and any significant time 
interactions was used to determine adjusted hazard rates and 95% confidence 
intervals for each time interval.  Mutually adjusted odds ratios and 95% confidence 
intervals for potential risk factors were also calculated from this model. 
C. Results 
Study Demographics 
 During the study period (1 January, 2002 to 31 December, 2007) there were 
125,594 patients admitted to UNC Hospitals.  Among them, 11,041 (8.8%) people 
had mechanical ventilation.  Of those, 9,347 were on ventilation for at least two days 
on a medical, surgical, or pediatric service.  Forty-two percent were female, 57% 
were white, and 30% were Black (Table 12).  The average age at admission was 38 
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years (standard deviation (sd) 29).  There were an average of 1.5 (sd 1.3) ventilator 
placements per person for a total of 12,301 ventilator placements of at least two 
days duration. The median duration of ventilation per placement was 4 days 
(interquartile range (IQR) 2-8) with an average duration of ventilation per person of 
12 days (sd 26). 
Table 12. Characteristics of patients with ventilators at UNC Hospitals during 2002-2007. 
 
Number of 
people % 
Number 
people with 
VAP* 
Risk of VAP per 
100 people         
(95%CI*) 
Total 9347  416 4.45 (4.45, 4.46) 
Gender     
  Male 5465 58.5 238 4.35 (4.35, 4.36) 
  Female 3882 41.5 178 4.59 (4.57, 4.60) 
Race     
  White 5356 57.3 241 4.50 (4.49, 4.51) 
  Black 2842 30.4 130 4.57 (4.56, 4.59) 
  Hispanic 562 6.0 28 4.98 (4.90, 5.06) 
  Other races 587 6.3 17 2.90 (2.84, 2.95) 
People with ventilators by year     
  2002 1225 13.1 50 4.08 (4.05, 4.11) 
  2003 1496 16.0 68 4.55 (4.52, 4.57) 
  2004 1710 18.3 80 4.68 (4.65, 4.70) 
  2005 1782 19.1 88 4.94 (4.91, 4.96) 
  2006 1880 20.1 70 3.72 (3.70, 3.74) 
  2007 1851 19.8 60 3.24 (3.22, 3.26) 
Admissions per person (sd*)  1.09 (0.31)  1.06 (0.46)  
Ventilator placements per person 
(sd) 1.49 (1.28)  1.60 (1.50)  
Combined duration of ventilation per 
person, in days (sd) 12 (26)   19 (37)   
*VAP: ventilator-associated pneumonia; CI: confidence interval; sd: standard deviation. 
 
  Fifty-one percent of ventilator placements were in patients with at least one 
comorbidity (Table 13).  The most common comorbidities were acute respiratory 
distress syndrome (ARDS, 32.9%), trauma (9.6%), and cardiovascular complications 
(7.5%).  Most ventilator placements were initially located in the ICU (91.1%) and 
started on a surgical service (43.3%).  Few patients changed location (0.2%) or 
service (1.7%) while using a ventilator.   
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Table 13. Characteristics by ventilator placement for patients with ventilation at UNC Hospitals 
during 2002-2007. 
  
Number of 
ventilator 
placements 
% of 
placements 
Number of 
days with 
ventilation 
Number of  
VAP* 
Total 12301  86130 456 
Gender     
  Male 7195 58.5 50340 240 
  Female 5106 41.5 35790 179 
Race     
  White 7011 57.0 46835 243 
  Black 3816 31.0 28624 130 
  Hispanic 752 6.1 5155 29 
  Other race 722 5.9 5516 17 
Age (sd) 38 (29)   39 (27) 
Comorbidities     
  Average number (sd)  0.60 (0.65)   0.74 (0.71) 
  Cardiovascular Complications 927 7.5 4555 20 
  Trauma 1178 9.6 10174 71 
Acute Respiratory Distress                                 
Syndrome 
4052 32.9 36289 169 
  Acute Renal Failure 360 2.9 3212 13 
  Immunodeficiency 596 4.8 3303 18 
  Total number comorbidities     
    0 5977 48.6 37045 179 
    1 5277 42.9 39258 185 
    2 1019 8.3 9512 54 
    3 28 0.2 315 1 
Patient Location     
  ICU 11208 91.1 74818 385 
  Floor or step-down unit 1092 8.9 11303 34 
Number ventilator placements with 
at least one change 
29 0.2  1 
Hospital Service     
  Medicine 2978 24.2 19065 48 
  Surgery 5325 43.3 38156 264 
  Pediatric 3643 29.6 26848 96 
Number ventilator placements with 
at least one change 
215 1.7  13 
Median duration with concurrent 
central venous access (IQR) 
2 (1, 7)   6 (3, 12) 
Median duration with concurrent 
central venous catheter-associated 
blood-stream infection (IQR) 
0 (0, 0)   0 (0, 0) 
Median duration of ventilation (IQR) 
4 (2, 8)   7 (5, 14) 
*VAP: ventilator-associated pneumonia; sd: standard deviation; IQR: interquartile range. 
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Infection Rate 
 Among the 12,301 ventilator placements, there were 456 initial VAP cases.  
Overall, 4.5% of patients and 3.7% of all ventilator placements sustained an 
infection, resulting in an unadjusted, constant rate of 5.29 (95%CI 4.81, 5.78) VAP 
per 1000 ventilator-days (Table 14).  The median ventilation duration prior to VAP 
among patients developing pneumonia was 7 days (IQR 5-14). 
Table 14. Characteristics by ventilator placement for patients with ventilation at 
UNC Hospitals during 2002-2007. 
  
VAP risk per 100 
placements            
(95%CI) 
VAP rate per 1000 
ventilator-days 
(95%CI) 
Total 3.71 (3.37, 3.88) 5.29 (4.81 5.78) 
Gender   
  Male 3.34 (2.92, 3.55) 4.77 (4.71, 4.83) 
  Female 3.51 (3.00, 3.76) 5.00 (4.93, 5.07) 
Race   
  White 3.47 (3.04, 3.68) 5.19 (5.12, 5.25) 
  Black 3.41 (2.83, 3.70) 4.54 (4.46, 4.62) 
  Hispanic 3.86 (2.48, 4.56) 5.63 (5.42, 5.83) 
  Other race 3.73 (2.62, 4.29) 3.08 (2.94, 3.23) 
Comorbidities   
  Cardiovascular Complications 2.16 (1.22, 2.63) 4.39 (4.20, 4.58) 
  Trauma 6.03 (4.67, 6.72) 6.98 (6.82, 7.14) 
Acute Respiratory Distress                                 
Syndrome 
4.17 (3.56, 4.48) 4.66 (4.59, 4.73) 
  Acute Renal Failure 3.61 (1.68, 4.59) 4.05 (3.83, 4.27) 
  Immunodeficiency 3.02 (1.65, 3.72) 5.45 (5.20, 5.70) 
  Total number comorbidities   
    0 2.99 (2.56, 3.22) 4.83 (4.76, 4.90) 
    1 3.51 (3.01, 3.76) 4.71 (4.64, 4.78) 
    2 5.30 (3.92, 6.00) 5.68 (5.53, 5.83) 
    3 3.57 (0.00, 7.08) 3.17 (2.55, 3.80) 
Patient Location   
  ICU 3.44 (3.10, 3.61) 5.15 (5.09, 5.20) 
  Floor or step-down unit 3.11 (2.08, 3.64) 3.01 (2.91, 3.11) 
Hospital Service   
  Medicine 1.61 (1.16, 1.84) 2.52 (2.45, 2.59) 
  Surgery 4.96 (4.37, 5.26) 6.92 (6.84, 7.00) 
  Pediatric 2.64 (2.12, 2.90) 3.58 (3.50, 3.65) 
*VAP: ventilator-associated pneumonia; sd: standard deviation; IQR: interquartile range. 
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Time-to-infection Analysis 
 Unadjusted life table estimates for time to VAP are shown in Table 15.  The 
rate of VAP rose steadily over the first week following placement, declined over the 
second week, rose to a second peak over the third week and leveled off with 
subsequent ventilator duration.   
Table 15.  Life table for ventilator-associated pneumonia (VAP) at UNC Hospitals during 2002-
2007. 
Cumulative 
duration of 
ventilator 
placement 
(days) 
Number of 
placements 
without VAP 
at beginning 
of interval 
VAP 
during 
interval 
Proportion   
(per 1000 
ventilator-
days) with 
VAP during 
interval 
95% 
Confidence 
Interval 
Proportion of 
ventilator 
placements 
without VAP 
at end of 
interval 
Standard 
Error 
2-3 12301 67 3.27 (2.49, 4.05) 0.99   
4-6 6509 129 7.85 (6.50, 9.20) 0.97 0.002 
7-9 3899 87 8.43 (6.66, 10.19) 0.95 0.003 
10-12 2670 38 5.30 (3.62, 6.98) 0.94 0.004 
13-15 1904 19 3.64 (2.01, 5.28) 0.93 0.004 
16-18 1450 20 4.98 (2.80, 7.16) 0.92 0.005 
19-21 1143 24 7.54 (4.54, 10.55) 0.90 0.006 
22-28 911 18 3.39 (1.83, 4.96) 0.88 0.007 
29-35 586 17 4.89 (2.57, 7.22) 0.85 0.009 
36+ 384 34 3.93 (2.61, 5.25) 0.78 0.015 
  
 Over half of ventilation durations were less than 6 days.  Less than 10% of 
ventilators were used for more than three weeks.  The number of incident VAP 
cases peaked on days 4-6 for a total of 129 VAP cases.  Over half of all VAP cases 
occurred by the ninth consecutive day of ventilation and nearly 75% occurred by day 
15. 
Modeling 
 Discrete-time hazards models were limited to the first five weeks (35 days) of 
ventilator duration.  Results from the unadjusted model yielded the same trends as 
those found with the life tables (Figure 6).  The rate of VAP initially rose to a peak on 
days 7-9 (rate: 8.42 per 1000 ventilator-days, 95%CI 6.83, 10.38), and then dipped 
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to a low on days 13-15 (rate 3.40 per 1000 ventilator-days, 95%CI 2.30, 5.03).  
Rates of VAP increased over the third week to a second peak on days 19-21 (rate: 
6.57 per 1000, 95%CI 4.57, 9.43).  Subsequent rates ranged 3.4 to 4.9 per 1000 
ventilator-days. Thus, the constant rate underestimated the cumulative incidence for 
most of the first three weeks of ventilation and was an overestimate with longer 
duration (Figure 7).  Adjusting for year of ventilator placement did not alter the trends 
in VAP by duration of ventilation.   
Figure 6. Rate (with 95%CI) of ventilator-associated pneumonia across duration of 
ventilation from unadjusted models. 
Unadjusted risk factor assessment 
 Initially, we conducted univariate analyses in which potential risk factors were 
added to the discrete-time hazards models individually to assess the effect on the 
rate of VAP throughout ventilator duration (Table 16).  Compared to white patients, 
constant rate 
changing rate 
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Figure 7. Cumulative incidence of ventilator-associated pneumonia across duration 
of ventilation from unadjusted models. 
 
odds of VAP for Hispanic patients were similar (odds ratio (OR): 1.06, 95%CI 0.73, 
1.56) while those for Black patients (OR 0.86, 95%CI 0.70, 1.06) and patients of 
other races (OR 0.58, 95%CI 0.35, 0.96) were lower.  Odds of VAP were lower for 
patients on a floor or step-down unit compared to patients in the ICU (OR 0.56, 
95%CI 0.39, 0.80).  Older patients were more likely to contract VAP (OR per 10 year 
increase 1.03, 95%CI 1.00, 1.07).  There were too few ventilator placements among 
patients with diabetes, pulmonary complications, and sepsis to assess their potential 
as risk factors.  Patients with trauma (OR 1.50, 95%CI 1.15, 1.95) were more likely 
to have VAP than patients without trauma.  Patients with ARDS were less likely to 
have VAP than patients without ARDS (OR 0.86, 95%CI 0.70 1.04).  Other 
constant rate 
changing rate 
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comorbidities did not indicate an association with VAP over time.  Concurrent central 
venous catheter and ventilator use increased risk of VAP by 46% (OR 1.46 95%CI 
0.99, 2.16) and having a central venous catheter-associated blood-stream infection 
increased risk of VAP by 114% (OR 2.14 95%CI 1.58, 2.88).   
Table 16.  Odds ratios for risk factors of ventilator associated pneumonia. 
  
Univariate OR * 
(95%CI*) 
Fully adjusted OR 
(95%CI) 
Gender     
  Female ref* ref 
  Male 0.95 (0.78, 1.15) 0.89 (0.72, 1.08) 
Race   
  White ref ref 
  Black 0.86 (0.70, 1.06) 0.93 (0.75, 1.16) 
  Hispanic 1.06 (0.73, 1.56) 1.11 (0.73, 1.67) 
  Other race 0.58 (0.35, 0.96) 0.61 (0.36, 1.02) 
Age   
  50 years old ref ref 
  Per 10 year increase 1.03 (1.00, 1.07) 0.94 (0.88, 1.01) 
Patient location   
  ICU* ref ref 
  Floor or step-down unit 0.56 (0.39, 0.80) 0.33 (0.22, 0.50) 
Hospital service   
  Surgery  ref ref 
  First 11 days - Medicine 0.73 (0.40, 1.34) 0.61 (0.33, 1.13) 
  First 11 days - Pediatrics 1.10 (0.72, 1.68) 0.67 (0.38, 1.18) 
  After 11 days - Medicine 0.30 (0.21, 0.43) 0.30 (0.21, 0.43) 
  After 11 days - Pediatrics 0.38 (0.28, 0.50) 0.27 (0.17, 0.42) 
Comorbidities‡   
  Cardiovascular complications 1.01 (0.64, 1.58) 0.95 (0.59, 1.52) 
  Trauma 1.50 (1.15, 1.95) 1.60 (1.18, 2.17) 
Acute respiratory distress syndrome 
0.86 (0.70, 1.04) 0.99 (0.79, 1.23) 
  Acute renal failure 0.78 (0.46, 1.34) 0.86 (0.49, 1.51) 
  Immunodeficiency 1.21 (0.75, 1.94) 1.01 (0.62, 1.64) 
Concurrent central venous access 1.46 (0.99, 2.16) 1.51 (1.01, 2.25) 
Concurrent central venous catheter-
associated blood-stream infection 2.14 (1.58, 2.88) 1.88 (1.38, 2.56) 
*OR: odds ratio; CI: confidence interval; ref: reference level; ICU: intensive care unit. 
‡Reference groups for comorbidities are all patients without that comorbidity. 
 
 Averaged across the duration of ventilation, medical (OR 0.36, 95%CI 0.27, 
0.50) and pediatric patients (OR 0.51, 95%CI 0.40, 0.64) were less likely than 
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surgical patients to have VAP.  The effect of hospital service changed throughout 
ventilator duration, so we included separate terms in adjusted models for the effect 
of service through the eleventh day and after eleven days of ventilation.  In 
univariate analysis, prior to the eleventh day of ventilation, medical (OR 0.73, 95%CI 
0.40, 1.34) and pediatric patients (OR 1.10, 95%CI 0.72, 1.68) rates were not 
statistically different from those of surgical patients.  After 11 days of ventilation, 
medical (OR 0.30, 95%CI 0.21, 0.43) and pediatric patients (OR 0.38, 95%CI 0.28, 
0.50) had lower risk of VAP compared with surgical patients. 
Full model adjusted for all covariates 
 When adjusting for all covariates, the trends in VAP rate remained similar to 
the unadjusted trends across ventilator duration.  Rates increased in the first week to 
a high on days 7-9, then decreased to a low on days 13-15, peaked again on days 
19-21 and leveled to a relatively stable rate for any subsequent ventilation duration.   
 For example (Figure 8), rates of VAP among 50 year-old, white women with 
no comorbidities, in an ICU and on a surgical service throughout duration of 
ventilation (i.e. the ‘baseline’ group, in which all risk factors are at referent levels) 
peaked at 10.29 per 1000 ventilator-days (95%CI 6.38, 16.56) on days 7-9, dropped 
to 2.79 per 1000 ventilator-days (95%CI 1.47, 5.31) on days 13-15 and had a 
second peak of 5.93 per 1000 (95%CI 3.31, 10.62) on days 19-21.  The rate of VAP 
among this group was higher than the unadjusted rate (shown in Figure 6) for the 
first two weeks, then similar to the unadjusted rate with continuing ventilation.  In 
contrast, the rate of VAP among 20 year-old, white women with no comorbidities, on 
a floor or step-down unit and a medical service throughout the duration of ventilation 
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peaked at 2.14 per 1000 ventilator-days (95%CI 0.86, 5.30) on days 7-9.  With 
continuing ventilation, the rate ranged from 0.38 to 0.89 VAP per 1000 ventilator-
days.  The rate of VAP among this group was lower than the unadjusted rate 
throughout ventilator duration. 
Figure 8.  Estimated rate (with 95%CI) of ventilator-associated pneumonia across 
duration of ventilation among specified groups. 
 
 
 Adjusting for all other covariates (Table 16), having central venous catheter-
associated blood-stream infection constituted the greatest elevation of VAP rate (OR 
1.88, 95%CI 1.38, 2.56).  Rate of VAP was 30-40% lower in the first 10 days of 
ventilation when patients were on medical (OR 0.61, 95%CI 0.33, 1.13) or pediatric 
(OR 0.67, 95%CI 0.38, 1.18) rather than surgical services.  With subsequent 
ventilation duration VAP rate was 70% lower in medical (OR 0.30, 95%CI 0.21, 0.43) 
Legend: 
            50 year-old white women, ICU, surgical service, no comorbidities 
            20 year-old white women, floor, medical service, no comorbidities 
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and pediatric patients (OR 0.27, 95%CI 0.17, 0.42). VAP rate was higher when 
patients had a trauma (OR 1.60, 95%CI 1.18, 2.17), or had a concurrent central 
venous catheter (OR 1.51, 95%CI 1.01, 2.25) during their ventilator duration.  Males 
(OR 0.89, 95%CI 0.72, 1.08) and patients on floors (OR 0.33, 95%CI 0.22, 0.50) had 
lower incidence of VAP compared with females and patients in ICUs.  Race, age, 
and other comorbidities led to no change or inconclusive changes in VAP over the 
duration of ventilation.  
D. Discussion 
 Ventilator-associated pneumonia (VAP) is an important cause of morbidity 
and mortality in hospitalized patients, accounting for 26% of all hospital-associated 
infections, 83% of all pneumonias, and approximately 30% of nosocomial infection-
related mortality in the United States [1-2]. We found that the rate of VAP at UNC 
Hospitals in 2002-2007 varied across duration of ventilation.  We found a peak in 
VAP rate late in the first week of ventilation, a decrease through the second week, a 
second peak late in the third week, and a lower rate with continuing ventilation.  
Saviteer et al. [23] found a similar trend of increasing and decreasing rates when 
studying all nosocomial infections across duration of hospitalization.  Their 
measured trends were across a wider span, peaking around day 18 and dropping to 
day 24.  Jaimes [10] reported changing hazard rate specifically for VAP which more 
closely resembles our results.  We also found that these changes in rate of VAP 
over duration of ventilation remain when adjusting for risk factors.  
 Some risk factors have consistently been associated with increased VAP rate, 
including presence of a central venous catheter or primary blood-stream infection, 
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reintubation, aspiration, change of location within the hospital, tracheostomy, and 
patient positioning [4-5, 7, 9, 17, 24, 26-29].  Others, such as age, gender, hospital 
service, race/ethnicity, hospital service, and comorbidities have been identified as 
risk factors in some, but not all studies [5, 9, 10, 17, 27-28]. We did find that when 
accounting for the changing rate across ventilation duration, risk factors for VAP 
included gender, patient location, age, hospital service, trauma, and concurrent 
presence of a central venous catheter or central venous catheter-associated blood-
stream infection.   
 We only included one hospital in this analysis.  We were also unable to 
assess reintubation, aspiration, tracheostomy and patient positioning (i.e., head of 
bed >30o).  While these factors influence VAP, we do not expect them to play a role 
in VAP rate across ventilator duration.  Standard practices at this one hospital are 
maintained throughout hospitalization, thus we expect that the variation in VAP rate 
throughout ventilator duration would be seen at other facilities as well.  
 We assumed that gaps of up to two days in the duration of ventilation from 
the nursing assessment represented continuous use.  We conducted a separate 
analysis with more than a one-day gap considered to be removal and replacement of 
the ventilator.  Odds ratios for covariates in that analysis were similar to those in the 
main analysis.  Trends in VAP across duration of ventilation remained the same, 
with peaks at the end of the first and third weeks and a relative plateau with longer 
ventilator duration.   
 Ventilator placements with shorter duration may occur in healthier patients 
who are less likely to have infections, or they may occur in sicker patients who are 
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more likely to die before VAP occurs.  We did not analyze mortality data or other 
information on competing outcomes, so we were unable to elucidate the causes for 
the lower rates of VAP in the first few days of ventilation.  We did look at how the 
pool of patients changed across ventilator duration. The proportion of patients on a 
surgical service or with a trauma increased approximately 10% and the proportion of 
patients with concurrent central venous catheter-associated blood-stream infection 
increased 5% across five weeks of ventilation.  The proportion of patients in the ICU 
decreased from 91% to 71% over the five weeks analyzed.  The decrease in VAP on 
days 13-15 was not accompanied by a drastic change in any covariate. 
E. Conclusions 
 Duration of mechanical ventilation influences the rate of VAP.  Gender, 
patient location, hospital service, trauma, concurrent central venous catheter, and 
prior central venous catheter-associated blood stream infection affect the rate of 
VAP throughout ventilation duration.  Being aware of shifts in the patient population, 
monitoring at risk patients closely, and timing interventions appropriately could aid in 
decreasing the incidence of VAP. 
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 VII. RESULTS:  ANALYZING THE EFFECT OF DEVICE DURATION ON THE 
INCIDENCE OF VENTILATOR-ASSOCIATED PNEUMONIA 
 
A. Introduction  
 Many longitudinal data analyses assume a constant outcome rate over the 
duration of exposure.  This assumption is not always correct, but without a 
comparison model including changing rates over time, it is difficult to determine 
whether the constant-rate model assumption is appropriate for the data.   
 In some arenas, such as monitoring healthcare associated infections, 
assuming a constant risk (or incidence) of the outcome across the duration of 
exposure eases the data collection burden and facilitates the timely provision of 
surveillance numbers to monitor potential outbreaks [1-4].  However, it has been 
argued that using a constant rate model when the assumption of a constant rate 
across the duration of time is not met provides results that are “at best ambiguous, 
at worst misleading [1].”  In particular, if a changing infection rate peaks and then 
decreases over long hospitalizations, not accounting for this change could mean that 
following guidelines to decrease exposure time would decrease numbers of 
infections but lead to higher constant infection rates because lower risk days were 
removed from the rate calculation. 
 This paper uses one type of device-associated infection (ventilator-associated 
pneumonia) as our example for assessing models of changing infection rate across 
the duration of exposure.  Mechanical ventilators are among the medical devices 
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most commonly associated with nosocomial infection [2-4]. Infection rates are also 
not constant across duration of ventilation or hospitalization [5-8, Chapter VI].  
Despite this, many studies of hospital associated infections in the United States 
report a single, constant rate for ventilator-associated pneumonia (VAP) in each 
intensive care unit.   
 Our objective in this study was to determine the impact of modeling the 
changing VAP rate throughout duration of ventilation. We hypothesized that a 
changing VAP rate provides more meaningful incidence estimates than a model 
assuming a constant rate of infection throughout ventilator duration. 
B. Longitudinal Data Modeling Options 
 The analysis technique that is most commonly used for analysis of rates is 
the “constant rate” loglinear or Poisson regression model [9].  In its simplest form, 
this model assumes a constant outcome rate over the duration of exposure and 
the log of that rate is predicted by the linear vector of the regression covariates. The 
advantage of Poisson over logistic regression in longitudinal data analysis is that 
it accounts for variations in time at risk between patients. The disadvantage is that 
(unless time interactions are included) the outcome rate is presumed constant.  
 Cox proportional hazard regression allows for a changing (hazard) rate of 
the outcome over the duration of exposure.  However, because Cox regression is 
based on a semiparametric model, the statistical equations used to maximize the 
likelihood do not maximize the baseline hazard rate [9, 10].  Discrete-time hazards 
regression also accounts for a changing outcome rate across the duration of 
exposure and it includes the changing baseline rate in its maximum likelihood 
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functions [11].  It does assume that the hazard rate for the outcome is constant 
over each chosen time interval, however this is a less restrictive assumption than 
a constant rate over the entire observation period (used in the constant rate 
model).  Discrete-time hazards regression allows for direct estimation of the 
hazard function across the duration of exposure and allows for multiple time-
dependent variables to be incorporated directly into the dataset [11].  This paper 
compares constant-rate Poisson models, which are widely reported in literature 
[2-6], to discrete-time hazards models with varying time intervals. 
C. Example Study Data 
 This study included the 9,347 people who were hospitalized at UNC Hospitals 
between January 1, 2002 and December 31, 2007 and who used a mechanical 
ventilator for at least two days during their hospitalization.  Data were collected as 
part of usual hospital care.  Days of hospitalization and ventilation, gender, age, 
race/ethnicity, comorbidities derived from ICD-9 codes, patient location (ICU versus 
floor) on each day, and hospital service (medical, surgical, or pediatric) on each day 
were recorded for each patient.  VAP occurred in 456 patients across 104,443 
ventilator-days and 286,599 patient-days.  Further description on the cohort and 
main study results have been provided elsewhere (see ventilator manuscript for aim 
1). 
 For comparison of actual and model-predicted rates of VAP, we censored 
data after 35 days of ventilation or hospital stay, depending on measure of exposure 
duration.  The 35-day endpoint was chosen because there were few cases of VAP 
after this point.  The median ventilator duration was 4 days (IQR: 2-8) and the 
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median hospital stay was 7 days (IQR: 3-15).  The median time between admission 
and ventilator placement was 0 days (IQR: 0-7).  
D. Methods 
Duration of time exposed 
 The duration between hospital admission and the 35th day of ventilation or 
discharge date for each patient was used to calculate “ventilator-days.”  The first two 
days of ventilation were not included because two days of exposure are required 
before VAP can occur [12].  
Constant Rate Models 
 Unadjusted, constant rates of pneumonia across duration of ventilation were 
determined using a Poisson regression model including only the intercept.   
! 
rate = e
"  
This was equivalent to dividing the total number of pneumonias by the total duration 
of ventilation for all patients and is analogous to the constant rate models in the 
literature [2-4].  
Discrete-Time Hazards Model Overview 
 We also modeled the data using discrete-time hazards models to allow the 
rate of VAP to change across the duration of ventilation [13,14].  A discrete-time 
hazard is the conditional probability that an individual, i, will experience the event of 
interest, j, during a time period, T, given that the individual did not experience the 
event in an earlier time period.  The conditional rate of VAP in each discrete interval 
was the number of events in the interval divided by the number of units at risk (i.e. 
ventilator-days) during the interval. 
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! 
h
^
(t j ) =
number _of _VAPj
ventilator " days j
 
 Life tables were used to define a risk set and an associated hazard rate for 
each discrete time interval.  After determining the hazard rate for each time interval, 
logistic regression of the person-period dataset modeled the log odds of the hazard 
rate throughout the duration of exposure.     
! 
logit(h(tij )) ="1(Time_Period _1) +"2(Period _2) +"3(Period _ 3) + ...+"n (Period _ n)  
The αn represent the log of the odds for the baseline hazard rate associated with the 
discrete time intervals.  Thus, αn can be likened to the intercept of a logistic model, 
measured separately for each time interval.  
 Hazard rates were calculated for each time interval using the associated αn.   
! 
hazard
n
=
1
1+ e
("n )
 
Thus, discrete-time hazard models allowed us to estimate the changing rate of VAP 
across duration of hospitalization or ventilation. 
 Typically, the hazard for a discrete time period is the conditional probability of 
an event that can only occur once per patient.  VAP can occur multiple times in one 
person, one admission, or even during one ventilator placement.  We used 
generalized estimating equations [15] to account for multiple admissions or ventilator 
placements in one person and multiple VAP per placement.  Because only a few 
ventilator placements had more than one VAP, we used an exchangeable 
correlation matrix, requiring only one parameter, but allowing for non-zero correlation 
between multiple ventilator placements and VAP within a person. 
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Longer versus shorter time periods in discrete-time hazards models 
 We conducted two discrete-time hazards analyses.  The first had time periods 
of longer length to allow for smoothing and visualization of underlying trends.  The 
second used shorter time periods, lengthening later time periods due to sparse data 
with longer duration of exposure.   
 The longer period discrete-time hazards analysis split the duration of 
ventilation or hospitalization into three-day time periods for the first three weeks and 
seven-day time periods for the fourth and fifth weeks.  The shorter analysis time 
periods were one-day for the first 11 days, two-day for days 12-21, and seven-day 
with subsequent duration of exposure. 
F-tests comparing modeled rates of VAP 
 The rate from each of the three models was multiplied by the number of 
continuing ventilator placements in order to calculate an expected number of VAP 
for each day based on that rate.  The modeled rates were subtracted from the actual 
daily rate of infection for each day of exposure duration. The difference between the 
modeled rate and the actual rate was squared and summed across the duration of 
exposure to calculate the sum of squared error term for each of the three models.  F-
tests were used to compare the fit to the data of the three models (constant rate 
model, longer time interval discrete-time hazards model, and shorter time interval 
discrete-time hazards model). 
Comparing Poisson and discrete-time hazards models 
 In Poisson models, log rate ratios (constant across time) are estimated to 
compare index to reference levels for each covariate.  In discrete-time hazards 
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models, log odds of hazard ratios are estimated.  Because rates are small (less than 
10 per 1000 at all time points), the odds ratios of hazard rates approximate hazard 
rate ratios and we can utilize the asymptotic nature of the two models in order to 
compare the model estimates from the various models. 
Competing risks 
 VAP is not the only possible outcome for patients with mechanical ventilation.  
None of these models count for competing risks, such as death.  Also, since we did 
not have information about why ventilators were removed, patients who died during 
ventilation and patients who were well enough for ventilation removal are treated 
equally in these data.   
Specific subpopulations of interest 
 In addition to modeling the overall population, we assessed five subgroups to 
determine whether models performed differently for different groups of interest.  
These five subgroups were: patients over age 65, patients under age 18, patients in 
an intensive care unit (ICU), patients on a surgical service, and patients on a 
surgical service with a trauma diagnosis.   
Supplemental analyses using other denominators 
 Infection rates in many studies use the ventilator-day denominator required 
for CDC surveillance, but some use days in the hospital or “patient-days” as their 
denominator or only assess duration of exposure until first infection [4].  Thus, we 
also assessed differences in VAP across duration of hospitalization, and duration of 
ventilation/hospitalization until first infection.   
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E. Results 
 There were 425 VAPs in the first 35 days of ventilation. The number of VAP 
was highest on the fourth day of exposure (n=48) and the rate was highest on the 
sixth day (9.53 VAP per 1000 ventilator-days).  The rate of VAP increased over the 
first week, decreased in the second week, increased again in the third week, and 
was variable with subsequent duration due to small numbers of VAP each day.  Half 
of ventilator placements were less than five days, and 75% were less than 10 days.  
Half of VAP occurred on or before the ninth day of ventilation and 75% occurred by 
the 13th day.  Half of hospitalizations were less than 16 days, and 75% were less 
than 32 days.  Half of VAP occurred on or before the ninth day of hospitalization and 
75% of VAP occurred by the 19th day.   
Constant rate model 
 The constant infection rate across the first 35 days of ventilation was 5.22 per 
1000 ventilator-days (95% CI 4.72, 5.71). The same number of infections were 
predicted across the duration of ventilation as actually occurred.  The largest 
difference in expected and actual number of infections was on the sixth day of 
ventilation in which the constant rate predicted 25 VAP, but 45 occurred.  The 
largest rate difference between the constant rate model and the observed incidence 
also occurred at the end of the first week, when the actual VAP rate peaked (Figure 
9).  The predicted rate was higher than the actual rate of VAP for the first 3 days, 
then lower through day 11. With longer ventilator duration, the constant rate model 
generally overestimated the actual rate.   
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 The total error (sum of errors) across the duration was an excess of 17 VAP 
per 1000 ventilator-days (Table 17).  In the first 10 days, during which 75% of 
ventilator placements completed duration, the total error was a decrease of 13 VAP 
per 1000 ventilator-days (Table 18).   
 
Figure 9.  Actual and model-predicted rate of ventilator-associated pneumonia 
throughout duration of mechanical ventilation. 
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Table 17. Model performance across entire period of observation (35 days of ventilation)  
  Discrete-time hazards 
 Constant-rate 
Longer time-
periods 
Shorter time-
periods 
Number of parameters 
estimated 1 9 17 
Average error (per 1000 
ventilator-days) 0.53 0.11 0.14 
Sum of errors (per 1000 
ventilator-days) 17.86 3.99 4.71 
Sum of squared errors 0.000213 0.000108 0.000083 
 F-tests 
 
Longer vs. Shorter 
time- periods 
Longer time-
periods vs.  
Constant rate 
Shorter time- 
Periods vs 
Constant rate 
F-test 0.62 3.07 1.66 
p-value 0.75 0.01 0.16 
 
 
Discrete-hazards model with longer time periods 
 In the model with longer time periods, the predicted rate ranged between 3 
and 8 VAP per 1000 ventilator-days (Figure 9).  This model predicted 3 more VAP 
predicted than actually occurred across the 35 day duration of ventilation.  The 
largest difference between actual and predicted number of infections was on the 
second day, when the predicted number was 16 higher than the actual number of 
VAP.  The largest difference in rate between the predicted and actual VAP occurred 
on the 35th day of ventilation when no VAP occurred but 4 per 1000 ventilator-days 
(n=2) were expected.  The modeled rate was generally higher than the actual rate 
for the first 5 days, lower through day 10, then higher through day 19.  Differences 
between modeled and observed rates were generally larger in the last two weeks, 
when seven-day time intervals were used and the number of actual infections on any 
day was small. 
 The total error (sum of errors) across the duration of ventilation was an 
excess of 4 VAP per 1000 ventilator-days (Table 17).  In the first 10 days, the sum of 
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errors from the model were 4 per 1000 ventilator-days lower than the observed rate 
(Table 18).   
Table 18. Performance of model for subgroups of interest. 
  Discrete-time hazards 
 Constant-rate 
Longer time-
periods 
Shorter time-
periods 
Across first 10 days of mechanical ventilation  
Number of 
parameters estimated 
1 4 9 
Sum of errors (per 
1000 ventilator-days) 
-13.32 -3.69 2.31 
Sum of squared 
errors 
0.000059 0.000013 0.000006 
 F-tests 
 
Longer vs. Shorter 
time- periods 
Longer time-
periods vs.  
Constant rate 
Shorter time- 
Periods vs 
Constant rate 
F-test 0.24 5.82 1.10 
p-value 0.90 0.04 0.63 
    
Number of 
parameters 
estimated for all 
models below 
1 9 17 
Over 65 years old   
Sum of errors (per 
1000 ventilator-days) 
21.54 7.09 7.88 
Sum of squared 
errors 
0.000975 0.000767 0.000738 
 F-tests 
 
Longer vs. Shorter 
time- periods 
Longer time-
periods vs.  
Constant rate 
Shorter time- 
Periods vs 
Constant rate 
F-test 0.09 0.85 0.34 
p-value 0.99 0.57 0.98 
Under 18 years old   
Sum of errors (per 
1000 ventilator-days) 
-6.82 -17.59 -17.62 
Sum of squared 
errors 
0.000413 0.000324 0.000299 
 F-tests 
 
Longer vs. Shorter 
time- periods 
Longer time-
periods vs.  
Constant rate 
Shorter time- 
Periods vs 
Constant rate 
F-test 0.18 0.86 0.41 
p-value 0.99 0.56 0.96 
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Table 18. continued. Performance of model for subgroups of interest. 
ICU 
Sum of errors (per 
1000 ventilator-days) 
15.43 5.02 5.54 
Sum of squared 
errors 
0.000284 0.000154 0.000131 
 F-tests 
 
Longer vs. Shorter 
time- periods 
Longer time-
periods vs.  
Constant rate 
Shorter time- 
Periods vs 
Constant rate 
F-test 0.38 2.61 1.23 
p-value 0.92 0.03 0.34 
Surgical Service    
Sum of errors (per 
1000 ventilator-days) 
51.00 24.22 28.74 
Sum of squared 
errors 
0.000681 0.000312 0.000273 
 F-tests 
 
Longer vs. Shorter 
time- periods 
Longer time-
periods vs.  
Constant rate 
Shorter time- 
Periods vs 
Constant rate 
F-test 0.31 3.69 1.59 
p-value 0.95 0.01 0.18 
Surgical service and Trauma diagnosis   
Sum of errors (per 
1000 ventilator-days) 
57.41 37.04 38.28 
Sum of squared 
errors 
0.001502 0.001065 0.001005 
 F-tests 
 
Longer vs. Shorter 
time- periods 
Longer time-
periods vs.  
Constant rate 
Shorter time- 
Periods vs 
Constant rate 
F-test 0.13 1.28 0.53 
p-value 0.99 0.30 0.90 
 
Discrete-hazards model with shorter time periods  
 In the model with shorter time periods, the modeled rate ranged between 2 
and 9 VAP per 1000 ventilator-days.  The largest difference between the actual and 
predicted number of infections was on days 8 and 9, when five fewer VAP were 
expected from the model than actually occurred.  The largest rate difference 
between the modeled and actual VAP was on the 35th day of ventilation (Figure 9).  
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As with the larger time period discrete-hazard model, there were zero actual VAP, 
but 4 per 1000 ventilator-days were expected from the model.  
 The total error (sum of errors) across the duration of ventilation was an 
excess of 5 VAP per 1000 ventilator-days (Table 17).  In the first 10 days, the sum of 
errors from the model were 2 per 1000 ventilator-days lower than the observed rate 
(Table 18). 
Comparison of models 
 Residual differences between the shorter time period discrete-time hazards 
model and the observed incidence were consistently smaller than the longer time 
period model and the constant rate model.  While all of the models overestimated 
the actual incidence, models that allowed flexibility in measuring rate across the 
duration of ventilation were a better fit to the data than the constant rate model 
(Table 17).  The average error for discrete-hazards models was approximately one-
quarter of that in the constant model.   
 Over 75% of ventilator placements had been removed by the end of the tenth 
day.  During this time, all of the models underestimated the actual VAP rate 
conditional on continuing ventilator duration.  The constant rate model had larger 
sum of squared error, total error, and average error than the variable rate models.  
 The F-test comparing the constant rate model to the longer time period 
discrete-time hazards model was statistically significant across the entire 35 days 
(Table 17) and the first 10 days of ventilation (Table 18), indicating better fit of the 
changing rate model.  The F-test comparing the constant rate model to the shorter-
time period discrete-time hazards model did not provide a statistically significant 
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better fit to the observed incidence.  The constant rate model does not account for 
the variation in VAP rate over duration of exposure, but the shorter-time period 
model includes too much random error for estimating trends in the data. Thus, for 
ventilator-days, the changing rate model with longer time periods provides the best 
fit to the observed incidence. 
F. Patient subgroups 
 Selected patient groups for comparison of models across duration of time 
All models underestimated VAP rate across the duration of ventilation for patients 
under age 18 (Table 18).  All models overestimated VAP rates for patients over age 
65, in the ICU, on surgical service, and on a surgical service with trauma diagnosis.  
While models were consistently over- or underestimated the rate, the magnitude of 
the constant rate model was smaller among patients under 18 and larger for all other 
groups of interest when compared to the changing rate models.  The F-test indicated 
that the longer time period changing rates model was a better fit to the actual VAP 
rate for ICU and surgical service patients.  The changing rate models did not have a 
statistically better fit than the constant rate model among patients with younger or 
older ages or among surgical patients with a trauma diagnosis.  
G. Other denominators 
 Results were replicated in using duration of hospitalization and duration of 
ventilation/hospitalization prior to infection as denominators.  For all denominator 
choices, at least one of the changing rates models were statistically a better fit than 
the constant rate model when accounting for time at risk. 
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H. Discussion 
 In this study, we compared constant and variable rate models to observed 
incidence for VAP throughout duration of ventilation and hospitalization.  The actual 
rate of VAP, conditional on continuing ventilation or hospitalization, changed across 
time.  While all models overestimated the observed incidence, models that allowed 
flexibility in measuring rate across time had approximately half of the sum of squared 
error compared to the constant rate model (Table 17).  The average error for 
discrete-hazards models was less than one-third of that in the constant model.   
 Over 75% of ventilator placements had been removed by the end of the tenth 
day of ventilation.  During this initial 10-day period, all of the models underestimated 
the actual VAP rate conditional on continuing ventilator duration. 
 The degree to which each model underestimated the VAP rate during the first 
ten days was at least half as large as the degree to which it was overestimated 
across the total duration studied (35 days).  Inclusion of these longer-lasting 
ventilator placements in the data decreased the estimated constant rate.  Thus, the 
benefit of the changing rate models was that earlier time periods were more 
accurately modeled without being influenced by extended ventilation.   
 Limiting to selected patient groups, ventilator-day models performed similarly 
to the overall population.  In all situations in which a single model was a superior, the 
longer time period changing rate model was the best predictor of the observed 
incidence.  In three of the target groups, including both of those based on age, the 
three models did not have statistically different fit to the observed incidence.  The 
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constant rate model was also a poorer estimate of the actual VAP rate in target 
groups across the duration of hospitalization and the duration at risk.  
Ideally, all data used to compare across different patient populations or 
different hospitals should be adjusted for the changing rate of VAP across ventilator 
duration.  This is frequently not possible, since the duration of device placement for 
each person is often unavailable.  Without data on duration of ventilation and the day 
of VAP, it is impossible to know whether it is important to account for the time-
varying nature of the incidence of VAP and other device-related infections.  Thus, 
investigators should be aware that bias may be introduced when comparing 
differences between patient groups within a hospital, or comparing between 
hospitals without accounting for differences in rate across device exposure.  
I. Conclusion 
 Most surveillance reports assume a constant rate model.  In some target 
populations, there is not enough variation among the modeling strategies to warrant 
accounting for changes across the duration of ventilation or hospitalization. 
However, in some populations, including the overall population with ventilators at 
UNC Hospitals, there is sufficient variation in rate of VAP over duration of ventilation 
and hospitalization to warrant accounting for the changing rate.  Investigators 
comparing different hospitals, or patient subgroups within a hospital, should be 
aware that bias may be introduced by failing to account for the time-varying nature of 
device-related infection rates. 
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VIII. RESULTS:  SUPPLEMENTAL RESULTS FOR ANALYZING THE EFFECTS 
OF DEVICE DURATION AND EXPOSURE DEFINITION 
 
A. Scope of Chapter  
 This chapter is intended to cover the results for specific aim 2 which were not 
included in the previous chapter.  It consists of five main sections: 
a.  Results for the effect of patient characteristics on ventilator-associated 
pneumonia (VAP) rates as measured by ventilator-days 
b.  Results for the effect of exposure definition (i.e. denominator choice) on 
ventilator-associated pneumonia (VAP) 
c.  Results for the effect of patient characteristics on central line-associated 
bloodstream infections (CLABSI) as measured by line-days  
d.  Results for the effect of device duration on CLABSI  (assessed across 8 
weeks (56 days)) 
e.  Results for the effect of denominator choice on CLABSI 
 This chapter is not intended to provide information in a format appropriate for 
publication.  Rather, since the results of the device duration analysis were similar 
across mechanical ventilator and central line associated infections and across 
different denominator choices, the tables and graphs in this chapter are intended as 
supplemental material for the previous results chapter. 
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Each section begins with a short paragraph summarizing the tables and graphs to 
follow and noting any differences from the results of “Analyzing the effect of device 
duration on the incidence rate of ventilator-associated pneumonia.”  
B. Effect of covariates on rate of VAP 
 Across the three analysis methods, increased rate of VAP over the duration of 
ventilation was associated with being in an ICU, on a surgical service, trauma 
complication, having a central line and having a central line-associated blood-stream 
infection (Table 19 shows rate ratios for ventilator-days).  The three models led to 
similar conclusions about covariates, and the estimated coefficients and width of 
confidence intervals did not vary considerably across covariates.  While all 
confidence intervals between the models overlapped the estimates of the other 
models, the constant rate model implied greater risk of VAP in patients with central 
lines and less risk increase associated with central line-associated blood-stream 
infection.  This might be due to the estimation of ever concurrently having a central 
line versus estimating concurrent presence of a central line during each time period 
in the discrete-time hazards models.  In the constant-rate model, initial location and 
hospital service were included rather than as time-dependent variables (like they 
were included in discrete-time hazards models and in previous manuscripts).  While 
these variables were allowed to change, very few did over the course of one 
ventilation placement, thus the estimates from the constant and changing-rate 
models are fairly comparable. 
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Table 19.  Comparison of rate ratios* across VAP models.   
Fully Adjusted Model Rate Ratios*                                                      
(95% Confidence Intervals) 
Poisson Discrete-time hazards 
Covariates Constant Rate 
Longer  
Time-Periods 
Shorter  
Time-Periods 
Gender       
  Female ref ref ref 
  Male 0.87 (0.72, 1.07) 0.88 (0.73, 1.06) 0.88 (0.73, 1.06) 
Race    
  White ref ref ref 
  Black 0.97 (0.78, 1.20) 0.94 (0.77, 1.16) 0.94 (0.76, 1.15) 
  Hispanic 1.11 (0.74, 1.65) 1.11 (0.75, 1.64) 1.11 (0.76, 1.64) 
  Other race 0.65 (0.40, 1.07) 0.64 (0.40, 1.04) 0.95 (0.59, 1.32) 
Age    
  50 years old ref  ref ref 
  Per 10 year increase 0.94 (0.88, 1.00) 0.95 (0.89, 1.01) 0.95 (0.89, 1.00) 
Patient location    
  ICU 2.86 (1.94, 4.21) 2.58 (1.78, 3.73) 2.59 (1.80, 3.75) 
  Floor or step-down unit ref ref ref 
Hospital service    
  Medicine ref ref ref 
  Surgery  3.31 (2.37, 4.61)   
  Pediatrics 1.14 (0.70, 1.85)   
  First 11 days - Surgery N/A 1.24 (0.74, 2.06) 3.51 (2.38, 5.18) 
    Pediatrics N/A 1.08 (0.60, 1.93) 1.30 (0.71, 2.39) 
  After 11 days - Surgery N/A 3.06 (2.18, 4.29) 1.05 (0.64, 1.75) 
    Pediatrics N/A 0.97 (0.59, 1.59) 1.03 (0.54, 1.96) 
Comorbidities^    
  Cardiovascular complications 0.87 (0.54, 1.39) 0.97 (0.63, 1.51) 1.00 (0.64, 1.56) 
  Trauma 1.49 (1.10, 2.01) 1.63 (1.24, 2.14) 1.62 (1.23, 2.12) 
  Acute respiratory distress 
    syndrome 
1.07 (0.87, 1.33) 0.95 (0.77, 1.15) 0.95 (0.78, 1.16) 
  Acute renal failure 0.94 (0.53, 1.65) 0.79 (0.44, 1.41) 0.79 (0.44, 1.40) 
  Immunodeficiency 0.97 (0.60, 1.57) 1.04 (0.68, 1.60) 1.06 (0.69, 1.62) 
Concurrent central line 1.96 (1.07, 3.58) 1.39 (0.96, 2.00) 1.35 (0.94, 1.96) 
Concurrent central line-
associated blood-stream 
infection 
1.36 (1.02, 1.82) 1.77 (1.34, 2.32) 1.77 (1.35, 2.33) 
* Discrete-hazards models provide "odds of hazard rate ratios." Since rates are small, we 
assume that the rate ratios and odds of hazard rate ratios are approximately equal and 
comparable across models to determine trends. 
^Reference level for comorbidities and concurrent central line variables is all ventilator 
placements without that comorbidity or concurrent central line. 
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C. Effect of denominator choice on VAP 
Reason for assessment 
 Infection rates in many studies use the ventilator-day denominator required 
for national surveillance reporting, but some use days in the hospital or “patient-
days” as their denominator [4].  VAP also does not necessitate removal of the 
device, and multiple infections are possible, so a patient may contribute time to the 
ventilator-day or patient-day denominators after infection occurs.  There is a 
possibility that some studies only include duration of exposure prior to infection as 
their time-at-risk.  Therefore, we assessed these different denominator choices to 
determine whether changing rate models were appropriate across all options for 
defining exposure-time.  
Findings 
 As with ventilator-days, all denominator choices indicated that changing rate 
models were better estimates of the observed incidence for at least one subgroup 
assessed.    
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Table 20. Summary of error in models compared to observed across different 
denominators for ventilator-associated-pneumonia. 
  Discrete-time hazards 
Patient-days Constant-rate 
Longer time-
periods 
Shorter time-
periods 
Average error (per 
1000 patient-days) 
0.25 0.09 0.03 
Sum of errors (per 
1000 patient-days) 
8.51 3.28 1.11 
Sum of squared 
errors 
0.000033 0.000012 0.000008 
 
Longer vs. 
Shorter time- 
periods 
Longer time-
periods vs.  
Constant rate 
Shorter time- 
Periods vs 
Constant rate 
F-test 1.03 5.34 3.21 
p-value 0.45 <0.01 0.01 
Ventilator-days-at-risk     
Average error (per 
1000 ventilator-days) 3.10 0.02 0.02 
Sum of errors (per 
1000 ventilator-days) 
10.55 0.83 0.79 
Sum of squared 
errors 
0.000238 0.000153 0.000095 
 F-tests 
 
Longer vs. 
Shorter time- 
periods 
Longer time-
periods vs.  
Constant rate 
Shorter time- 
Periods vs 
Constant rate 
F-test 1.28 1.74 1.55 
p-value 0.32 0.14 0.18 
Patient-days-at-risk    
Average error (per 
1000 patient-days) 0.25 0.07 0.01 
Sum of errors (per 
1000 patient-days) 
8.47 2.43 0.22 
Sum of squared 
errors 
0.000011 0.000001 <0.000001 
 F-tests 
 
Longer vs. 
Shorter time- 
periods 
Longer time-
periods vs.  
Constant rate 
Shorter time- 
Periods vs 
Constant rate 
F-test 1.04 4.49 2.79 
p-value 0.45 <0.01 0.02 
 
 
 
 
 105 
Table 21. Summary of error in models compared to actual VAP across patient-days for 
subgroups of interest. 
  Discrete-time hazards 
 Constant-rate 
Longer time-
periods 
Shorter time-
periods 
Across first 10 days of hospitalization 
Sum of errors (per 
1000 patient-days) 
-6.16 0.21 0.03 
Sum of squared 
errors 
0.000012 0.000001 <0.000001 
 F-tests 
 
Longer vs. Shorter 
time- periods 
Longer time-
periods vs.  
Constant rate 
Shorter time- 
Periods vs 
Constant rate 
F-test 878.98 15.23 5569.99 
p-value 0.03 <0.01 0.01 
Over 65 years old    
Sum of errors (per 
1000 patient-days) 
7.20 -0.15 -2.57 
Sum of squared 
errors 
0.000084 0.000063 0.000055 
 F-tests 
 
Longer vs. Shorter 
time- periods 
Longer time-
periods vs.  
Constant rate 
Shorter time- 
Periods vs 
Constant rate 
F-test 0.29 1.05 0.55 
p-value 0.96 0.43 0.88 
Under 18 years old    
Sum of errors (per 
1000 patient-days) 
4.69 1.62 0.36 
Sum of squared 
errors 
0.000033 0.000027 0.000025 
 F-tests 
 
Longer vs. Shorter 
time- periods 
Longer time-
periods vs.  
Constant rate 
Shorter time- 
Periods vs 
Constant rate 
F-test 0.15 0.71 0.33 
p-value 0.99 0.68 0.98 
ICU    
Sum of errors (per 
1000 patient-days) 
8.93 3.32 1.16 
Sum of squared 
errors 
0.000036 0.000013 0.000009 
 F-tests 
 
Longer vs. Shorter 
time- periods 
Longer time-
periods vs.  
Constant rate 
Shorter time- 
Periods vs 
Constant rate 
F-test 0.84 5.41 2.98 
p-value 0.58 <0.01 0.02 
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Table 21 cont. Summary of error in models compared to actual VAP across patient-days 
for subgroups of interest. 
  Discrete-time hazards 
 Constant-rate 
Longer time-
periods 
Shorter time-
periods 
Surgical service    
Sum of errors (per 
1000 patient-days) 
17.33 9.22 5.98 
Sum of squared 
errors 
0.000110 0.000045 0.000031 
 F-tests 
 
Longer vs. Shorter 
time- periods 
Longer time-
periods vs.  
Constant rate 
Shorter time- 
Periods vs 
Constant rate 
F-test 0.97 4.51 2.72 
p-value 0.49 <0.01 0.02 
Surgical service and trauma diagnosis   
Sum of errors (per 
1000 patient-days) 
22.15 21.59 17.47 
Sum of squared 
errors 
0.000381 0.000256 0.000230 
 F-tests 
 
Longer vs. Shorter 
time- periods 
Longer time-
periods vs.  
Constant rate 
Shorter time- 
Periods vs 
Constant rate 
F-test 0.24 1.51 0.70 
p-value 0.98 0.20 0.77 
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Table 22. Summary of error in models compared to actual VAP across ventilator-
days-at-risk for subgroups of interest. 
  Discrete-time hazards 
 Constant-rate 
Longer time-
periods 
Shorter time-
periods 
Across first 10 days of mechanical ventilation   
Sum of errors (per 1000 
ventilator-days) 
-12.73 4.35 -0.17 
Sum of squared errors 0.000063 0.000015 0.000001 
 F-tests 
 
Longer vs. 
Shorter time- 
periods 
Longer time-
periods vs.  
Constant rate 
Shorter time- 
Periods vs 
Constant rate 
F-test 7.70 5.18 20.15 
p-value 0.27 0.05 0.18 
Over 65 years old    
Sum of errors (per 1000 
ventilator-days) 
20.91 11.23 12.56 
Sum of squared errors 0.001080 0.000884 0.000860 
 F-tests 
 
Longer vs. 
Shorter time- 
periods 
Longer time-
periods vs.  
Constant rate 
Shorter time- 
Periods vs 
Constant rate 
F-test 0.06 0.70 0.27 
p-value 0.99+ 0.69 0.99 
Under 18 years old    
Sum of errors (per 1000 
ventilator-days) 
-15.31 31.54 -24.58 
Sum of squared errors 0.000535 0.000439 0.000397 
 F-tests 
 
Longer vs. 
Shorter time- 
periods 
Longer time-
periods vs.  
Constant rate 
Shorter time- 
Periods vs 
Constant rate 
F-test 0.22 0.68 0.37 
p-value 0.98 0.70 0.98 
ICU    
Sum of errors (per 1000 
ventilator-days) 
4.05 -2.67 -1.75 
Sum of squared errors 0.000354 0.000232 0.000204 
 F-tests 
 
Longer vs. 
Shorter time- 
periods 
Longer time-
periods vs.  
Constant rate 
Shorter time- 
Periods vs 
Constant rate 
F-test 0.28 1.66 0.78 
p-value 0.96 0.16 0.69 
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Table 22. cont. Summary of error in models compared to actual VAP across 
ventilator-days-at-risk for subgroups of interest. 
  Discrete-time hazards 
 Constant-rate 
Longer time-
periods 
Shorter time-
periods 
Surgical service    
Sum of errors (per 1000 
ventilator-days) 
48.60 30.27 31.75 
Sum of squared errors 0.000742 0.000405 0.000363 
 F-tests 
 
Longer vs. 
Shorter time- 
periods 
Longer time-
periods vs.  
Constant rate 
Shorter time- 
Periods vs 
Constant rate 
F-test 0.25 2.60 1.11 
p-value 0.98 0.03 0.41 
Surgical service and trauma diagnosis   
Sum of errors (per 1000 
ventilator-days) 
46.86 46.21 47.15 
Sum of squared errors 0.001724 0.001370 0.001288 
 F-tests 
 
Longer vs. 
Shorter time- 
periods 
Longer time-
periods vs.  
Constant rate 
Shorter time- 
Periods vs 
Constant rate 
F-test 0.14 0.81 0.36 
p-value 0.99+ 0.60 0.98 
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Table 23. Summary of error in models compared to actual VAP across patient-days-
at-risk for subgroups of interest. 
  Discrete-time hazards 
 Constant-rate 
Longer time-
periods 
Shorter time-
periods 
Across first 10 days of hospitalization 
Sum of errors (per 
1000 patient-days) -5.76 0.18 <0.01 
Sum of squared 
errors 0.000011 0.000001 <0.000001 
 F-tests 
 
Longer vs. Shorter 
time- periods 
Longer time-
periods vs.  
Constant rate 
Shorter time- 
Periods vs 
Constant rate 
F-test 751890 15.052 4713900 
p-value 0.001 0.006 <0.01 
Over 65 years old    
Sum of errors (per 
1000 patient-days) 7.65 -0.75 -3.19 
Sum of squared 
errors 0.000097 0.000074 0.000066 
 F-tests 
 
Longer vs. Shorter 
time- periods 
Longer time-
periods vs.  
Constant rate 
Shorter time- 
Periods vs 
Constant rate 
F-test 0.25 0.96 0.49 
p-value 0.97 0.49 0.92 
Under 18 years old   
Sum of errors (per 
1000 patient-days) 4.58 1.20 -0.14 
Sum of squared 
errors 0.000034 0.000030 0.000027 
 F-tests 
 
Longer vs. Shorter 
time- periods 
Longer time-
periods vs.  
Constant rate 
Shorter time- 
Periods vs 
Constant rate 
F-test 0.18 0.50 0.27 
p-value 0.99 0.84 0.99 
ICU    
Sum of errors (per 
1000 patient-days) 8.88 2.48 0.27 
Sum of squared 
errors 0.000036 0.000015 0.000010 
 F-tests 
 
Longer vs. Shorter 
time- periods 
Longer time-
periods vs.  
Constant rate 
Shorter time- 
Periods vs 
Constant rate 
F-test 0.87 4.65 2.66 
p-value 0.56 <0.01 0.03 
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Table 23. cont. Summary of error in models compared to actual VAP across patient-
days-at-risk for subgroups of interest. 
  Discrete-time hazards 
 Constant-rate 
Longer time-
periods 
Shorter time-
periods 
Surgical service    
Sum of errors (per 
1000 patient-days) 18.32 8.55 5.22 
Sum of squared 
errors 0.000114 0.000051 0.000036 
 F-tests 
 
Longer vs. Shorter 
time- periods 
Longer time-
periods vs.  
Constant rate 
Shorter time- 
Periods vs 
Constant rate 
F-test 0.86 3.90 2.29 
p-value 0.57 <0.01 0.05 
Surgical service and trauma diagnosis   
Sum of errors (per 
1000 patient-days) 24.64 23.01 18.74 
Sum of squared 
errors 0.000408 0.000294 0.000265 
 F-tests 
 
Longer vs. Shorter 
time- periods 
Longer time-
periods vs.  
Constant rate 
Shorter time- 
Periods vs 
Constant rate 
F-test 0.24 1.20 0.58 
p-value 0.98 0.34 0.86 
 
D. Effect of covariates on rate of CLABSI 
 Across the three analysis methods, increased rate of CLABSI over the 
duration of central line placement was associated with Black or other race (not 
Hispanic), being in an ICU, on a surgical service, acute respiratory distress 
syndrome, and acute renal failure (Table 24 shows rate ratios for central line-days).  
The three models led to similar conclusions about covariates, and the estimated 
coefficients and width of confidence intervals did not vary considerably across 
covariates.  In the constant-rate model, initial location and hospital service were 
included rather than as time-dependent variables (like they were included in 
discrete-time hazards models and in the previous manuscript).  While these 
variables were allowed to change, very few did over the course of one central line 
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placement, thus the estimates from the constant and changing-rate models are 
comparable. 
Table 24.  Comparison of rate ratios* across CLABSI models.   
Fully Adjusted Model Rate Ratios*                                                      
(95% Confidence Intervals) 
Poisson Discrete-time hazards 
Covariates Constant-Rate 
Longer Time- 
Periods 
Shorter Time- 
Periods 
Gender       
  Female ref ref ref 
  Male 1.11 (0.99, 1.23) n/a n/a 
  Male < 7 days n/a 1.32 (1.12, 1.54) 1.34 (1.13, 1.60) 
  Male > 7 days n/a 0.98 (0.85, 1.13) 0.96 (0.83, 1.12) 
Race    
  White ref ref ref 
  Black 1.32 (1.18, 1.48) 1.37 (1.22, 1.54) 1.37 (1.22, 1.54) 
  Hispanic 1.05 (0.82, 1.33) 1.07 (0.83, 1.38) 1.07 (0.83, 1.39) 
  Other race 1.41 (1.14, 1.75) 1.40 (1.11, 1.77) 1.40 (1.11, 1.77) 
Age    
  50 years old ref  ref ref 
  Per 10 year increase 0.98 (0.95, 1.02) 1.01 (0.98, 1.05) 1.01 (0.98, 1.05) 
Patient location    
  Floor or step-down unit ref ref ref 
  ICU 1.36 (1.20, 1.53) 1.32 (1.16, 1.48) 1.31 (1.16, 1.48) 
Hospital service    
  Medicine ref ref ref 
  Surgery  1.15 (1.01, 1.31) 1.15 (1.00, 1.31) 1.14 (1.00, 1.31) 
  Pediatrics 0.86 (0.67, 1.10) 0.63 (0.45, 0.90) 0.63 (0.45, 0.89) 
  Other 0.47 (0.31, 0.71) 0.46 (0.30, 0.71) 0.47 (0.30, 0.72) 
Comorbidities^    
  Cardiovascular complications 0.63 (0.47, 0.84) 0.64 (0.47, 0.86) 0.64 (0.47, 0.87) 
  Trauma 0.99 (0.78, 1.25) 1.00 (0.77, 1.28) 1.00 (0.78, 1.28) 
  Acute respiratory distress 
    syndrome 1.15 (1.00, 1.32) 1.09 (0.95, 1.26) 1.09 (0.95, 1.26) 
  Acute renal failure 1.29 (0.99, 1.68) 1.30 (0.99, 1.72) 1.30 (0.99, 1.71) 
  Immunodeficiency 0.87 (0.72, 1.04) 0.88 (0.72, 1.08) 0.88 (0.72, 1.08) 
* Discrete-hazards models provide "odds of hazard rate ratios." Since rates are small, we 
assume that the rate ratios and odds of hazard rate ratios are approximately equal and 
comparable across models to determine trends. 
^Reference level for comorbidities and concurrent central line variables is all ventilator 
placements without that comorbidity or concurrent central line. 
 
E. Effect of device duration on CLABSI 
 As with ventilator-days, the constant rate central-line day models were 
associated with more error than the changing rate models.  The F-test comparing 
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the constant rate model to the shorter-time period discrete-hazards model did not 
provide a statistically significant better fit to the observed incidence (Table 7).  But, 
the F-test comparing the constant rate to the longer-time period model was 
statistically significant across the 8 weeks of duration assessed.  Thus, for central 
line-days, as for ventilator-days, the changing rate model with longer time periods 
provides the best fit to the observed incidence.  The constant rate model does not 
account for the variation in CLABSI rate over the duration of exposure, but the 
shorter-time period changing rate model includes too much random error for 
estimating trends in the data.   
 The only subgroup with statistically significant F-tests indicating better fit for 
the changing rate models was the assessment of the first 10 days of central line 
placement.  Thus, it appears that no subgroup of patients drives the overall variation 
in CLABSI rate across duration of central line placement.  In this case, bias may be 
introduced when comparing the overall group of UNC Hospitals patients to only a 
subset of patients without accounting for the changing rate across device placement. 
Table 25. Summary of error in models compared to actual CLABSI across central line-
days. 
  Discrete-time hazards 
 Constant-rate 
Longer time-
periods 
Shorter time-
periods 
Average error (per 1000 
central line-days) -1.52 -0.05 -0.03 
Sum of errors (per 1000 
central line-days) -85.11 -2.83 -1.45 
Sum of squared errors 0.000359 0.000175 0.000160 
 F-tests 
 
Longer vs. Shorter 
time- periods 
Longer time-
periods vs.  
Constant rate 
Shorter time- 
Periods vs 
Constant rate 
F-test 0.12 4.19 0.96 
p-value 0.99+ <0.01 0.55 
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Table 26. Summary of error in models compared to actual CLABSI across central line-
days for subgroups of interest. 
  Discrete-time hazards 
 Constant-rate 
Longer time-
periods 
Shorter time-
periods 
Across first 10 days of central line placement  
Sum of errors (per 1000 
central line-days) 
1.06 0.02 0.03 
Sum of squared errors 0.000014 0.000003 <0.000001 
 F-tests 
 
Longer vs. Shorter 
time- periods 
Longer time-
periods vs.  
Constant rate 
Shorter time- 
Periods vs 
Constant rate 
F-test 4277 6.56 12205 
p-value 0.01 0.03 0.01 
Over 65 years old    
Sum of errors (per 1000 
central line-days) -96.88 -7.15 -4.86 
Sum of squared errors 0.001921 0.001693 0.001689 
 F-tests 
 
Longer vs. Shorter 
time- periods 
Longer time-
periods vs.  
Constant rate 
Shorter time- 
Periods vs 
Constant rate 
F-test <0.01 0.54 0.11 
p-value 0.99+ 0.87 0.99+ 
Under 18 years old    
Sum of errors (per 1000 
central line-days) -82.13 -14.90 -14.33 
Sum of squared errors 0.000730 0.000542 0.000502 
 F-tests 
 
Longer vs. Shorter 
time- periods 
Longer time-
periods vs.  
Constant rate 
Shorter time- 
Periods vs 
Constant rate 
F-test 0.10 1.39 0.35 
p-value 0.99+ 0.21 0.99+ 
ICU    
Sum of errors (per 1000 
central line-days) -75.34 0.52 1.27 
Sum of squared errors 0.000602 0.000439 0.000406 
 F-tests 
 
Longer vs. Shorter 
time- periods 
Longer time-
periods vs.  
Constant rate 
Shorter time- 
Periods vs 
Constant rate 
F-test 0.10 1.49 0.37 
p-value 0.99+ 0.17 0.99+ 
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Table 26. cont. Summary of error in models compared to actual CLABSI across central 
line-days for subgroups of interest. 
  Discrete-time hazards 
 Constant-rate 
Longer time-
periods 
Shorter time-
periods 
Surgical service    
Sum of errors (per 1000 
central line-days) -58.59 24.01 25.49 
Sum of squared errors 0.000547 0.000512 0.000519 
 F-tests 
 
Longer vs. Shorter 
time- periods 
Longer time-
periods vs.  
Constant rate 
Shorter time- 
Periods vs 
Constant rate 
F-test -0.015 0.27 0.04 
p-value n/a 0.99 0.99+ 
Surgical service and trauma diagnosis   
Sum of errors (per 1000 
central line-days) -4.05 67.48 69.55 
Sum of squared errors 0.002142 0.002313 0.002377 
 F-tests 
 
Longer vs. Shorter 
time- periods 
Longer time-
periods vs.  
Constant rate 
Shorter time- 
Periods vs 
Constant rate 
F-test -0.03 -0.30 -0.08 
p-value n/a n/a n/1 
 
F. Effect of denominator choice on CLABSI 
 Constant rate models were appropriate for many subgroups with all of the 
different denominators for central line exposure.  But, as with ventilators and central 
line-days, all denominator choices indicated that changing rate models were better 
estimates of the observed incidence for at least the overall group at UNC Hospitals 
or one subgroup assessed.    
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Table 27. Summary of error in models compared to actual CLABSI across different 
denominators for central line duration. 
  Discrete-time hazards 
Patient-days Constant-rate 
Longer time-
periods 
Shorter time-
periods 
Average error (per 
1000 patient-days) -0.45 -0.07 -0.07 
Sum of errors (per 
1000 patient-days) -25.26 -4.05 -3.83 
Sum of squared errors 0.000062 0.000036 0.000032 
 F-tests 
 
Longer vs. 
Shorter time- 
periods 
Longer time-
periods vs.  
Constant rate 
Shorter time- 
Periods vs 
Constant rate 
F-test 0.14 2.95 0.73 
p-value 0.99+ 0.01 0.80 
Central line-days-at-risk     
Average error (per 
1000 central line-days) -1.3 -0.02 0.01 
Sum of errors (per 
1000 central line-days) -72.64 -1.20 0.78 
Sum of squared errors 0.000331 0.000195 0.000178 
 F-tests 
 
Longer vs. 
Shorter time- 
periods 
Longer time-
periods vs.  
Constant rate 
Shorter time- 
Periods vs 
Constant rate 
F-test 0.12 2.78 0.67 
p-value 0.99+ 0.01 0.86 
Patient-days-at-risk 
Average error (per 
1000 patient-days) -0.37 -0.03 -0.02 
Sum of errors (per 
1000 patient-days) -20.76 -1.63 -1.30 
Sum of squared errors 0.000064 0.000038 0.000033 
 F-tests 
 
Longer vs. 
Shorter time- 
periods 
Longer time-
periods vs.  
Constant rate 
Shorter time- 
Periods vs 
Constant rate 
F-test 0.18 2.76 0.73 
p-value 0.99+ 0.01 0.79 
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Table 28. Summary of error in models compared to actual CLABSI across patient-
days for subgroups of interest. 
  Discrete-time hazards 
 Constant-rate 
Longer time-
periods 
Shorter time-
periods 
Across first 10 days of hospitalization 
Sum of errors (per 
1000 patient-days) 
2.75 -0.01 -0.04 
Sum of squared 
errors 
0.000010 0.000002 <0.000001 
 F-tests 
 
Longer vs. Shorter 
time- periods 
Longer time-
periods vs.  
Constant rate 
Shorter time- 
Periods vs 
Constant rate 
F-test 936.9 9.390 3558 
p-value 0.025 0.011 0.01 
Over 65 years old    
Sum of errors (per 
1000 patient-days) -19.52 0.32 -1.19 
Sum of squared 
errors 0.000298 0.000282 0.000279 
 F-tests 
 
Longer vs. Shorter 
time- periods 
Longer time-
periods vs.  
Constant rate 
Shorter time- 
Periods vs 
Constant rate 
F-test 0.01 0.23 0.05 
p-value 0.99+ 0.99 0.99+ 
Under 18 years old   
Sum of errors (per 
1000 patient-days) -19.09 -1.82 -1.02 
Sum of squared 
errors 0.000122 0.000084 0.000096 
 F-tests 
 
Longer vs. Shorter 
time- periods 
Longer time-
periods vs.  
Constant rate 
Shorter time- 
Periods vs 
Constant rate 
F-test -0.15 1.801 0.21 
p-value n/a 0.08 0.99+ 
ICU    
Sum of errors (per 
1000 patient-days) -15.96 1.29 -168.6 
Sum of squared 
errors 0.000103 0.000083 0.000605 
 F-tests 
 
Longer vs. Shorter 
time- periods 
Longer time-
periods vs.  
Constant rate 
Shorter time- 
Periods vs 
Constant rate 
F-test -1.04 0.96 -0.64 
p-value n/a 0.49 n/a 
 
 
 117 
Table 28. cont. Summary of error in models compared to actual CLABSI across 
patient-days for subgroups of interest. 
  Discrete-time hazards 
 Constant-rate 
Longer time-
periods 
Shorter time-
periods 
Surgical service    
Sum of errors (per 
1000 patient-days) -10.82 4.36 3.49 
Sum of squared 
errors 0.000148 0.000142 0.000142 
 F-tests 
 
Longer vs. Shorter 
time- periods 
Longer time-
periods vs.  
Constant rate 
Shorter time- 
Periods vs 
Constant rate 
F-test <0.01 0.17 0.03 
p-value 0.99+ 0.99+ 0.99+ 
Surgical service and trauma diagnosis   
Sum of errors (per 
1000 patient-days) 23.98 28.09 28.33 
Sum of squared 
errors 0.000387 0.000417 0.000411 
 F-tests 
 
Longer vs. Shorter 
time- periods 
Longer time-
periods vs.  
Constant rate 
Shorter time- 
Periods vs 
Constant rate 
F-test 0.02 -0.29 -0.05 
p-value 0.99+ n/a n/a 
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Table 29. Summary of error in models compared to actual CLABSI across central line-
days-at-risk for subgroups of interest. 
  Discrete-time hazards 
 Constant-rate 
Longer time-
periods 
Shorter time-
periods 
Across first 10 days of central line-placement    
Sum of errors (per 1000 
central line-days) 
-0.11 0.06 <-0.01 
Sum of squared errors 0.000014 0.000003 <0.000001 
 F-tests 
 
Longer vs. Shorter 
time- periods 
Longer time-
periods vs.  
Constant rate 
Shorter time- 
Periods vs 
Constant rate 
F-test 2835655 6.52 8051666 
p-value <0.01 0.03 0.01 
Over 65 years old    
Sum of errors (per 1000 
central line-days) -105.6 -27.13 -24.25 
Sum of squared errors 0.002614 0.002371 0.002356 
 F-tests 
 
Longer vs. Shorter 
time- periods 
Longer time-
periods vs.  
Constant rate 
Shorter time- 
Periods vs 
Constant rate 
F-test <0.01 0.41 0.09 
p-value 0.99+ 0.94 0.99+ 
Under 18 years old    
Sum of errors (per 1000 
central line-days) -56.89 0.61 1.73 
Sum of squared errors 0.000681 0.000539 0.000500 
 F-tests 
 
Longer vs. Shorter 
time- periods 
Longer time-
periods vs.  
Constant rate 
Shorter time- 
Periods vs 
Constant rate 
F-test 0.09 1.06 0.28 
p-value 0.99+ 0.42 0.99+ 
ICU    
Sum of errors (per 1000 
central line-days) -61.40 3.06 4.45 
Sum of squared errors 0.000604 0.000493 0.000461 
 F-tests 
 
Longer vs. Shorter 
time- periods 
Longer time-
periods vs.  
Constant rate 
Shorter time- 
Periods vs 
Constant rate 
F-test 0.08 0.90 0.24 
p-value 0.99+ 0.55 0.99+ 
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Table 29. cont. Summary of error in models compared to actual CLABSI across central 
line-days-at-risk for subgroups of interest. 
  Discrete-time hazards 
 Constant-rate 
Longer time-
periods 
Shorter time-
periods 
Surgical service    
Sum of errors (per 1000 
central line-days) -45.43 27.72 29.79 
Sum of squared errors 0.000544 0.000562 0.000563 
 F-tests 
 
Longer vs. Shorter 
time- periods 
Longer time-
periods vs.  
Constant rate 
Shorter time- 
Periods vs 
Constant rate 
F-test -0.01 -0.13 -0.03 
p-value n/a n/a n/a 
Surgical service and trauma diagnosis   
Sum of errors (per 1000 
central line-days) -5.00 63.78 66.62 
Sum of squared errors 0.002142 0.002294 0.002373 
 F-tests 
 
Longer vs. Shorter 
time- periods 
Longer time-
periods vs.  
Constant rate 
Shorter time- 
Periods vs 
Constant rate 
F-test -0.04 -0.26 -0.08 
p-value n/a n/a n/a 
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Table 30. Summary of error in models compared to actual CLABSI across patient-
days-at-risk for subgroups of interest. 
  Discrete-time hazards 
 Constant-rate 
Longer time-
periods 
Shorter time-
periods 
Across first 10 days of hospitalization 
Sum of errors (per 
1000 patient-days) 
1.91 -0.03 <-0.01 
Sum of squared 
errors 
0.000009 0.000002 <0.000001 
 F-tests 
 
Longer vs. Shorter 
time- periods 
Longer time-
periods vs.  
Constant rate 
Shorter time- 
Periods vs 
Constant rate 
F-test 27284 9.214 101987 
p-value 0.01 0.01 <0.01 
Over 65 years old    
Sum of errors (per 
1000 patient-days) -21.62 -5.88 -5.44 
Sum of squared 
errors 0.000333 0.000310 0.000308 
 F-tests 
 
Longer vs. Shorter 
time- periods 
Longer time-
periods vs.  
Constant rate 
Shorter time- 
Periods vs 
Constant rate 
F-test 0.01 0.30 0.06 
p-value 0.99+ 0.98 0.99+ 
Under 18 years 
old    
Sum of errors (per 
1000 patient-days) -11.34 1.88 2.29 
Sum of squared 
errors 0.000139 0.000097 0.000092 
 F-tests 
 
Longer vs. Shorter 
time- periods 
Longer time-
periods vs.  
Constant rate 
Shorter time- 
Periods vs 
Constant rate 
F-test 0.07 1.73 0.40 
p-value 0.99+ 0.10 0.99 
ICU    
Sum of errors (per 
1000 patient-days) -10.94 3.86 4.29 
Sum of squared 
errors 0.000115 0.000090 0.000083 
 F-tests 
 
Longer vs. Shorter 
time- periods 
Longer time-
periods vs.  
Constant rate 
Shorter time- 
Periods vs 
Constant rate 
F-test 0.10 1.12 0.30 
p-value 0.99+ 0.37 0.99+ 
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Table 30. cont. Summary of error in models compared to actual CLABSI across 
patient-days-at-risk for subgroups of interest. 
  Discrete-time hazards 
 Constant-rate 
Longer time-
periods 
Shorter time-
periods 
Surgical service    
Sum of errors (per 
1000 patient-days) -9.21 5.50 5.75 
Sum of squared 
errors 0.000123 0.000120 0.000118 
 F-tests 
 
Longer vs. Shorter 
time- periods 
Longer time-
periods vs.  
Constant rate 
Shorter time- 
Periods vs 
Constant rate 
F-test 0.02 0.11 0.04 
p-value 0.99+ 0.99+ 0.99+ 
Surgical service and trauma diagnosis   
Sum of errors (per 
1000 patient-days) 24.54 28.51 28.74 
Sum of squared 
errors 0.000429 0.000464 0.000458 
 F-tests 
 
Longer vs. Shorter 
time- periods 
Longer time-
periods vs.  
Constant rate 
Shorter time- 
Periods vs 
Constant rate 
F-test 0.02 -0.30 -0.05 
p-value 0.99+ n/a n/a 
  
IX. CONCLUSIONS 
A. Recapitulation of overall study aims, findings and degree to which the 
goals of the doctoral research have been met 
 The focus of this dissertation research has been on determining whether and 
how the rate of device-associated nosocomial infections change across duration of 
time at risk.  We focused specifically on central line and mechanical ventilator 
associated infections, as these devices are associated with many nosocomial 
infections and over 60% of nosocomial infection related mortality. 
 The dissertation had two specific aims.  The first was to clarify how the rate of 
device-associated infections varies over time in the hospital for patients who utilize 
ventilators or CL.  We achieved this aim by merging the electronic health and claims 
records from patients at UNC Hospitals between 2002 and 2007 and determining the 
time from device insertion to infection and device removal for these patients.  We 
then assessed and modeled the changing rate of CLABSI and VAP across duration 
of time with each device.  Further, we adjusted for changes in risk factor distribution 
across the duration of device use to clarify the extent to which risk factors 
determined rate of infection. 
 This aim was realized by the writing of two manuscripts, one for each type of 
device.  In the first manuscript, we assess the rate of CLABSI across 8 weeks of 
central line placement.  The rate of CLABSI increased from 1.60 per 1000 CL-days 
in the first three days to 5.07 per 1000 CL-days in the beginning of the third week 
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with a central line.  After dropping to 4.12 per 1000 CL-days in the fourth week, 
CLABSI increased again to 5.58 per 1000 CL-days among patients who had CL for 
seven weeks.  Rates of CLABSI across the duration of central line placement were 
similar among whites and Hispanics, among trauma and non-trauma patients, and 
among immunodeficient and non-immunodeficient patients.  CLABSI rate increased 
among blacks and other races compared with whites.  CLABSI rate also increased 
among ICU patients, surgical and pediatric patients compared with medical patients, 
and was higher in patients with acute respiratory distress syndrome and acute renal 
failure.  Children (under age 16) and older patients (1% increase in risk with each 
decade of life) were at increased risk of CLABSI across the duration of central line 
placement.  Males differed from females in that they were at increased risk of 
CLABSI in the first week, but with subsequent central line duration both genders had 
similar risk of CLABSI. 
 The second manuscript reported VAP across the first five weeks of 
mechanical ventilation.  The rate of VAP increased from 3.27 per 1000 ventilator-
days in the first three days with a ventilator to 8.43 per 1000 ventilator-days at the 
beginning of the second week.  As with CLABSI, there was a dip and another peak, 
but with VAP this occurred in a shorter time frame.  VAP reached 7.54 per 1000 
ventilator-days at the end of the third week then decreased to 4-5 per 1000 across 
the fifth week and with subsequent ventilation.  Males had a slightly lower VAP rate 
across the duration of ventilation compared with females; patients with 
cardiovascular complications, acute respiratory distress syndrome, acute renal 
failure, or immunodeficiency were similar to those without those conditions.  White, 
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black, and Hispanic patients had similar rates of VAP across duration of ventilation.  
Increasing age and being on a floor or step-down unit rather than in an ICU 
decreased risk of VAP across duration of ventilation.  Trauma patients and those 
with concurrent CL or CLABSI were at increased risk for VAP.  Medical and pediatric 
patients were less likely to have VAP than surgical patients.  After 11 days of 
ventilation, the risk of VAP among medical and pediatric patients decreased further 
compared with surgical patients.   
 The second specific aim was to determine the impact of denominator choice 
and modeling the changing infection rate over time for ventilator-associated 
pneumonia and central line-associated blood stream infections on the infection rates 
obtained.  We accomplished this through comparing constant and changing rate 
models of VAP and CLABSI using two types of denominators.  The device-day 
denominator was used in the first aim and accounted for the duration of time 
between device placement and removal.  A patient-day denominator accounted for 
the duration of time between admission and discharge.  We also assessed the 
impact of risk adjustment on denominator and modeling choice by including risk 
factors in our analyses. 
 The manuscript for this aim focused on VAP and a supplemental results 
chapter provided information on CLABSI.  As expected, patient-day models 
consistently indicated lower rates of infection across the duration of hospitalization 
compared with device-day models.  For both VAP and CLABSI, unadjusted, 
constant rate models had approximately twice the sum of squared error across 
duration of device placement compared to changing rate models.  When looking at 
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risk factors of interest, constant rate device-day models continued to have higher 
error compared with changing rate device-day models. The constant and changing 
rate models led to similar conditional rate ratios among covariates.  But, the 
increased error associated with the constant rate model implied that it was a poor 
choice for monitoring the rate of these infections throughout device and hospital 
duration.  Results from F-tests indicated that constant rate models were appropriate 
for many subgroups with all of the different denominators for both MV and CL.  But, 
for both devices, all denominator choices indicated that changing rate models were 
better estimates of the observed incidence for at least the overall group at UNC 
Hospitals or at least one subgroup assessed.   Comparison of these groups without 
adjusting for variation in rate over the duration of device exposure would lead to 
biased estimates. 
B. Strengths 
 The three previous studies in time to nosocomial infection have been limited 
by small numbers, examining only ICU patients, short duration of time studied, use 
of patient-days as denominator of choice, and, in the largest study to date, all 
nosocomial infections were included.  The two prior studies of time to device-
associated nosocomial infection both assessed VAP.  Cook, et al. presented data on 
VAP in 1,014 ICU patients from Canada between 1992 and 1996.  Jaimes, et al. 
presented data on VAP in 270 patients from Columbia between 2002 and 2003.  
Both of these studies used Cox proportional hazards regression, used a 
denominator comprising duration between admission and ICU discharge, and 
provided information on changing rate of VAP for less than 20 days with ventilation.  
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Saviteer, et al. assessed time to any nosocomial infection between admission and 
discharge among 102,665 patients at UNC Hospitals from 1980 to 1984 and 
provided information on the changing rate of nosocomial infection across 23 days of 
hospitalization. 
 A strength of this research is that we have extended the previous work in 
each of the following aspects:   
 1) Six years of data provided us with over 9,000 ventilated patients and over 
27,000 patients with CL.  The number of ventilated patients is much larger 
than studies to date.  And, this is the first study of time to CLABSI to our 
knowledge.  These larger numbers allowed us to assess changes in rate of 
infection as well as adjust for changes in risk factor distribution over duration 
of device use. 
 2) Secondary analysis of hospital-wide surveillance provided records of both ICU 
and floor or step-down unit patients.  While most ventilated patients are 
located in an ICU, some patients on a floor or step-down unit are ventilated 
and VAP can still occur on the floor when a patient is transferred from an ICU.  
Central line use is prevalent in both the ICU and floor or step-down units.  
Assessing these device-associated infections throughout the hospital 
provided us with a complete picture of VAP and CLABSI rates at UNC 
Hospitals. 
 3) The larger number of patients allowed us to assess infections across longer 
duration of device use.  Prior studies provided information about changing 
rate of infection for less than three weeks.  Many patients use a ventilator or 
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central line for a longer period of time.  We were able to assess changes in 
the rate of VAP for up to 5 weeks with mechanical ventilation and changes in 
CLABSI for up to 8 weeks of central line use. 
 4) Collection of data regarding duration of device usage allowed us to assess 
and compare device-days and patient-days.  While national surveillance of 
VAP and CLABSI uses device-day denominators, previous time to infection 
studies have utilized patient-day denominators.  The work in this dissertation 
provided manuscripts of time to infection across only the duration of device 
use and then compared duration of device use to duration of admission as 
potential denominator choices.    
 5) Conducting this study in a tertiary-care center with low rates of nosocomial 
infection allowed us to update the literature while providing current incidence 
data to which new interventions can be compared.  Rates of nosocomial 
infection have been decreasing in the past several years and patient safety 
goals include decreasing these rates.  Thus, timely data from a hospital with 
low rates can identify potential points of intervention given the current 
situation in a hospital adhering to guidelines.   
 An additional strength of the dissertation research is its specific focus on 
timing of infection.  Because previous information on time to infection in published 
literature has been a byproduct of other research questions, proportional hazards 
regression has been utilized.  Other studies assessing risk factors for VAP and 
CLABSI have used logistic regression.  While both of these models can be 
appropriate for studying exposure-outcome relationships, neither of them allows for 
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explicit modeling of conditional infection rates across the duration of device use.  
Logistic regression does not allow for assessing time-dependent risk factors.  
Proportional hazards regression does allow for time dependent covariates and 
accounts for changing rates over time.  But, it uses a partial likelihood technique to 
determine hazard ratios, thus not optimizing the models for the underlying 
conditional hazard rates.  We used discrete-time hazards analysis for our studies, 
allowing us to explicitly model the underlying conditional rate across duration of 
device use.  In addition, this type of model is comparable to logistic regression and 
provided us with log odds of hazard ratios for risk factors, which could be compared 
to other literature.  
C. Limitations 
 While obtaining electronic health records and claims data from UNC Hospitals 
allowed us to assess timing of CLABSI and VAP in thousands of patients over six 
years, it also provided some limitations for our analyses.   
1) The electronic data did not include information on the number of CL that 
patients had, only that at least one central line was present.  Thus, we were 
unable to determine whether patients with central line(s) were more likely to 
have CLABSI if they had more lines or whether the timing of CLABSI different 
with more CL.  This lack of information about number of CL is typical of this 
literature.  In the future, determining the increase in risk of CLABSI with each 
central line insertion would help to fill this knowledge gap.  
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2) The electronic data did not include information on aspiration.  Since aspiration 
is a known risk factor of VAP, we were unable to assess whether the timing of 
VAP varied by whether patients had aspiration. 
3) Device utilization was captured from daily nursing assessment.  This data 
included gaps when assessment information was not entered.  We assumed 
that gaps equivalent to the definition-based time requirements for attributing 
blood-stream infection and pneumonia to CL and MV, respectively, could be 
considered continuous use.  When extending “continuous” use to gaps of 5 
days, 70% of device placements were still included.  But, we felt that this gap 
was too long and represented removal and replacement rather than forgetting 
to enter an electronic record of the assessment for multiple days.   
4) The electronic data did not provide information on occurrences outside of the 
hospital setting.  If patients came into the hospital with a central line, we were 
unable to determine this with the electronic data.  We assessed whether this 
influenced our assessment of time to CLABSI by including a sensitivity 
analysis using only patients who had at least one day between admission and 
central line use.  If patients had either a central line or ventilator removed just 
before leaving the hospital, they could have a device-associated infection 
outside the hospital which would not be captured in our data.  We were 
unable to assess the incidence of this occurrence.  
5) We did not have access to other outcomes, such as death, which would 
compete with device-associated nosocomial infection.  Thus, patients who did 
not get infections because they died look similar to patients who had the 
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device removed because they were well enough for discharge.  Accounting 
for comorbidities and ICU versus floor or step-down unit allowed us to adjust 
for some patient severity information, but did not fully capture differences 
between those more and less likely for device-associated infections or more 
severe competing outcomes. 
 A potential source of error is not capturing CLABSI or VAP or including an 
infection when one has not occurred.  Clinical suspicion and laboratory confirmation 
of CLABSI and VAP are included in their definitions and infection control nurses and 
doctors review each case before it is entered into the Hospital Infection Database.  
Thus, it is unlikely that false positives are entered or false negatives are missed in 
the data.  The date of each infection is the date that the laboratory test was taken.  It 
is possible that the date entered into the database is the date of laboratory 
confirmation, but due to multiple reviews, this is also unlikely. 
D. Public Health Impact 
 While the public health impact of a single study is difficult, if not impossible, to 
assess, this project has provided insight into timing of MV and CL-associated 
nosocomial infections.  Variation in rate of infection is measurable, even when 
accounting for changing risk factors across device duration and with all typical 
exposure-time assessments.  Thus, there are time-periods during which patients are 
at increased risk and during which they may benefit from more intense, targeted 
interventions.  This study provides a method for assessing baseline risk over 
exposed time for patients with general hospital devices and a framework around 
which future interventions can be built. 
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Ideally, all data used to compare across different patient populations or 
different hospitals should be adjusted for the changing rate of device-associated 
infections across duration of exposure.  This is often not possible, since the duration 
of device placement for each person is often unavailable.  Without data on duration 
of device placement and the day of infection, it is impossible to know whether it is 
important to account for the time-varying nature of the incidence rate of device-
related infections.  Thus, comparing differences between hospitals or patient groups 
within a hospital without accounting for differences in rate across device exposure 
can provide misleading results.  In order to provide a basis for comparison between 
hospitals and patient groups, analyses of surveillance data reported in published 
studies should include assessment of patient characteristics as well as timing of 
device utilization and subsequent infection. 
E. Future directions 
 Future analyses in this data should look at pathogen-specific infections.  
Staphylococcus infections (Staph.) occur earlier than Pseudomonas infections.  As 
the amount of Staph. and specifically oxacillin-resistant Staph. present in hospitals 
and communities is increasing, the rate of device-associated infections may be 
increasing because more patients are exposed to Staph. while using CL or MV.  If 
Staph. infections make up an increasing proportion of infections throughout the six 
years in this data, then Staph. may be an appropriate intervention target. 
 Given our finding that time to CLABSI is longer than time to VAP, analysis of 
time to infection among patients with urinary catheters, surgical site infections, and 
other specific nosocomial infections of interest would provide information to infection 
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control practitioners on when to expect increased risk and target interventions.  As 
most cases of nosocomial infection are associated with medical devices, further 
investigation on timing of device-associated infection adjusting for changes in risk 
factor distribution should be conducted to confirm timing of CLABSI and VAP as well 
as to find target times for intervention with other infection prone devices. 
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X. APPENDICES 
A. Residual Error Graphs  
 
Figure 10. Residual error in ventilator-associated pneumonia models across duration 
of ventilation. 
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Figure 11. Residual error in ventilator-associated pneumonia models across 
hospitalization. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 135 
Figure 12. Residual error in CLABSI models across duration of central line 
placement. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 136 
Figure 13. Residual error in CLABSI models across hospitalization. 
 
 
